Adherence in twice weekly therapy for childhood tuberculosis by Naude, James te Water
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Adherence 
in twice weekly therapy 
for childhood tuberculosis 
Jim te Water Naude, MB ChB 
Dissertation presented for the Degree of 
Master of Philosophy 
(Maternal and Child Health) 
in the Department of Paediatrics and Child Health 
Faculty of Health Sciences 
UNIVERSITY OF CAPE TOWN 
October 1997 
The copyright of this thesis vests in the author. No 
quotation from it or information derived from it is to be 
published without full acknowledgement of the source. 
The thesis is to be used for private study or non-
commercial research purposes only. 
Published by the University of Cape Town (UCT) in terms 
of the non-exclusive license granted to UCT by the author. 
Un
ive
rsi
ty 
f C
ap
e T
ow
n
Declaration by Candidate 
I, James Mark te Water Naude, hereby declare that the work on which this thesis is 
based is original (except where acknowledged otherwise) and that neither the whole 
work or any part of it has been or is being submitted for another degree in this or any 
other university. I empower the university to reproduce for the purposes of research 
either the whole or any portion of the contents rn any manner whatsoever. 
Signature: 
Date: 
2 
TABLE OF CONTENTS 
1. INTRODUCTION ................................................. 4 
2. LITERATURE REVIEW ............................................ 4 
2.1 Prologue ................................................. 5 
2.2 Background ............................................... 5 
2.3 Adherence as it relates to tuberculosis therapy .................... 6 
2.4 Literature on intermittent chemotherapy for tuberculosis ............ 20 
2.5 Studies on adherence in childhood tuberculosis .................. 32 
3. METHODS ..................................................... 36 
3.1 Definition of terms ......................................... 36 
3. 2 Study design and methods .................................. 37 
3.3 Drug administration procedure ............................... 40 
4. RESULTS ...................................................... 41 
5. DISCUSSION ................................................... 51 
5.1 Limitations ............................................... 51 
5.2 Discussion of Results ...................................... 54 
6. CONCLUSION .................................................. 57 
7. RECOMMENDATIONS ............................................ 58 
8. ACKNOWLEDGEMENTS .......................................... 60 
9. REFERENCES .................................................. 61 
9.1 Additional useful bibliography ................................ 69 
10. APPENDICES .................................................. 70 
3 
1. INTRODUCTION 
1.1 AIM 
This thesis examines the adherence to therapy as part of a clinical trial to determine 
the effectiveness of fully intermittent therapy for childhood tuberculosis. 
1.2 OBJECTIVES 
These were to determine 1) the effectiveness of fully twice weekly therapy in childhood 
pulmonary tuberculosis, 2) whether adherence rates would be affected by twice weekly 
dosing and 3) whether certain socio-demographic factors influenced adherence. 
1.3 HYPOTHESES 
The statistical null hypotheses were: 
There were no differences in a) the clinical outcome, b) the adherence rates between 
the two forms of treatment. 
2. LITERATURE REVIEW 
The literature review will be set out as follows: 
2.1 Prologue 
2.2 Background 
2.3 The literature on adherence as it relates to tuberculosis therapy 
2.4 Studies of intermittent chemotherapy for tuberculosis 
a) for adults 
b) for children 
2. 5 Studies on adherence in childhood tuberculosis. 
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2.1 Prologue 
The following quotations help to describe the importance of the subject: 
" ... poor compliance has been, and remains, the principal cause of treatment failure in 
both developing and developed nations." 38 - Grange in Tubercle and Lung Disease, 
1993. 
"Patient noncompliance has been identified as the most serious remaining problem in 
tuberculosis control, and it is a major obstacle in the elimination of the disease." 21 -
Cuneo in Clinics in Chest Medicine, 1989. 
"The reasons for noncom pliant behaviour are not well understood ... " 54 - Macharia in 
JAMA 1992, describing nonadherence in a wide range of diseases. 
"Poor patient adherence is a multifaceted problem" 12 - MMWR 1993. 
"It will be a long, long war" 9 - Bignall, writing in Tubercle on the occasion of the Robert 
Koch Centenary. 
2.2 Background 
Tuberculosis (TB) has been declared a global public health emergency, a heretofore 
unprecedented step by the World Health Organisation. 100 The province of the Western 
Cape of South Africa has one of the highest notified or reported tuberculosis incidence 
rates in the world - 865/100 000 in 1993 - and it is one of few areas with a rising 
tuberculosis incidence.37 The rate for the Cape Town metropole in 1993 was 787/100 
000. This was in the virtual absence of HIV/AIDS.24 Stellenbosch as part of that region 
is one of the most affected districts. 81 It is evident that there is a close relationship 
between the number of cases of infectious tuberculosis and the tuberculosis morbidity 
and mortality in children. 49 The Western Cape also has a very high rate of childhood 
tuberculosis - 901/100 000 in under 4s ( 1989 figures) 37 The rate for South Africa in the 
same period was 158/100 000. The ratio of childhood (under 15 years) to adult 
tuberculosis in the Western Cape in 1993 was 1 :3. 
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The reasons for embarking on a study to determine the effectiveness of fully 
intermittent therapy of childhood tuberculosis were: 
1) The best data published so far have either been too small in number (Kumar3) or 
have had too many dropouts from treatment (Biddulph8). In addition, very few studies 
have well documented adherence rates. 2) There was a need to ease the workload of 
the staff, and intermittent therapy was considered an appropriate method, but it needed 
to be researched. There were also considerations of cost reduction and increased 
convenience for the clients. 3) There was in addition the need to research tuberculosis 
in a rural setting, as the tuberculosis incidence in nearly all rural areas in the Western 
Cape was higher than in the urban areas. 37 This dissertation concentrated on 
adherence in children because of the dearth of scientific knowledge on this very 
important subject. The World Health Organisation has identified the need for 
operational research to apply and adapt proven technologies 98 On the topic of 
adherence as a whole, there were more than 8000 bibliographic entries for patient 
compliance by 1991, yet only 37 studies had been conducted in third world countries.
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2.3 Adherence as it relates to tuberculosis therapy 
Compliance is a term related to many spheres of human activity, eg. compliance with 
traffic regulations. Adherence also is not exclusively medical, and in contrast to 
compliance, is used in settings where slightly more volition is intended, as in religious 
adherents. 
Understandings of adherence and compliance 
Medically speaking, compliance is the technical term for doing as the doctor says, or 
more formally, "the extent to which a person's behaviour (in terms of taking 
medications, following diets, or executing life-style changes) coincides with medical or 
health advice." This is the definition of compliance given by the standard reference 
work on the subject, "Compliance in Health Care" by Haynes, Taylor and Sackett. 40 
This definition is insufficient according to Urquhart, 88 who believes that the time factor 
should be more explicitly taken into account and thus adherence should be properly 
defined as "the extent to which the time history of the patient's dosing corresponds to 
the prescribed regimen". 
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Chaulet, considering compliance in tuberculosis, adopts a different and wider 
perspective on the subject. He believes firstly15 that compliance (in addition to 
confonnity by the patient) also implies conformity between the treatment prescribed by 
the doctor and that called for by the national tuberculosis programme. He secondly 
believes 16 that in those countries where the prevalence of infection is intermediate or 
high, the principal responsibility for compliance resides not with the patient, but with the 
health providers at all levels. These problems of poor implementation of sound policy 
have been shown to exist in South Africa. 82 · 83· 101 It has been established that in the 
Western Cape considerable variation exists especially in the treatment of children with 
TB. 101 Wallace Fox has stated that national surveillance of actual tuberculosis practices 
was the most important measure in improving national standards in the management 
of tuberculosis. 33• 34 
Bignall also believes in adopting the wider outlook: "If after careful, sympathetic 
explanation they still don't want it, then something is wrong with the programme for 
those particular people in that particular environment".9 
In accord with these broader views on the subject, the terminology also has come under 
scrutiny: the term adherence has lately come into vogue as being the correct or 
appropriate term to use. This has occurred because of negative associations of the 
term compliance: "unworthy submission" as the Oxford Concise Dictionary puts it. It 
also has the connotation that the patient is merely "docile and subservient". 79 It is 
notable, however, that the "compliance" terminology is entrenched in the medical 
literature, along with such intolerant terms as delinquent, defaulter and dropout. Index 
Medicus lists Patient compliance, Patient cooperation, Patient dropouts and Treatment 
refusal as the related terms on this subject. Adherence is not a main subject heading, 
either there or in MEDLINE, the computer-based search modality. Another angle on 
adherence is that taken by Vander Stichele90 , who says that the measurement thereof 
is of cardinal importance in clinical trials. 
Adherence and compliance are used interchangeably in the literature, and have very 
similar meanings. However, because of the negative associations of the term 
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compliance, I have chosen to use the term adherence for this dissertation, and will limit 
the discussion to adherence by the patient. 
Adherence in tuberculosis will thus be further addressed as follows: 
2.3.1 Factors associated with adherence. 
2.3.2 Scope of the problem. 
2.3.3 Measuring adherence. 
2.3.4 Improvement strategies/ Management of nonadherence. 
2.3.5 Summary 
2.3.1 Factors associated with adherence. 
Sumartojo79 has recently reviewed the literature with respect to tuberculosis. She gives 
the following as conventional characteristics of nonadherents: homelessness, 
substance abuse, prior history of poor adherence, emotional disturbance, lack of 
transportation, behavioural problems, dissatisfaction with clinic scheduling, 
forgetfulness, mental retardation, lack of family or social support, migrant status, 
illiteracy, unemployment, low income, and minority status. This list would almost seem 
to contain characteristics generally definitive of tuberculosis sufferers, not only those 
nonadherentl 
Of interest here is that two recent studies in African rural areas have mentioned that 
male gender is a risk factor for nonadherence.91 · 93 
Sumartojo states that demographic factorsa are poor predictors of adherence and are 
in any case a) not inherently causal and b) cannot be altered by the treatment 
programme. Sumartojo stresses that the above list of those nonadherent is empirical 
and not analytical. Factors outside the control of the patient like environmental, 
a Such as age, sex, race, ethnicity, occupation, income, and education. 
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structural and operational considerations are not taken into account. There is a need 
to develop accurate predictive models of adherence, that are testable in field trials. She 
states in addition that it is important to challenge the conventional view that attributes 
adherence problems solely to the patient. Sumartojo cites studies which have looked 
specifically at adherence predictors in tuberculosis. The pretreatment factors identified 
were low income, low education, excessive use of alcohol and single status. 17 Again 
these factors are descriptive of many adult tuberculosis patients. 
However, the strongest predictor of adherence over 6 months was operational, namely 
adherence over the first month. 28 It is also noteworthy that a Montreal study found that 
adherence was improved in those who came for a follow-up within the first 4 weeks of 
therapy. 56 
Factors that produce good adherence 
Five general categories of factors studied have been identified - these have been 
reworked by Stone: 78 
1) Situational factors. 
These are economic, cultural, family and physical environment factors. The effects of 
these vary with circumstances, and are not amenable to easy change. Reviewing 
cultural factors specifically, Sumartojo found little common ground between cultures in 
terms of influences on adherence. She concludes with the assertion that the quality of 
services might well override any cultural influence on treatment outcome. 
2) Nature of the illness. 
Acute, painful and serious illnesses elicit the highest rates of adherence, and long 
duration chronic illnesses, like tuberculosis, elicit the lowest rates. 
3) Treatment regimen. 
As the complexity increases, adherence drops, worsening with the number of drugs and 
the frequency and complexity of administration. Once or twice daily therapy is clearly 
superior to thrice or four times daily.88 It is not clear whether daily or intermittent therapy 
- twice or thrice weekly - is the easier for the patient. In terms of how the treatment is 
administered, it is well established that supervised therapy clearly improves adherence 
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in patients with tuberculosis. 79 This needs no elaboration. Sumartojo states that directly 
observed therapy (DOT) has been shown to improve adherence in both research and 
day-to-day service situations. The effects of DOT, however, do not persist after 
supervision stops. 79 In the Phillippines, blister packs have been used successfully 
where DOT was not possible. 89 It is noteworthy that side-effects of treatment do not 
appear to have a negative impact on adherence - where side-effects are mentioned in 
a study, most often no parallel mention is made of related adherence effects. 47 In fact, 
one Hong Kong study states that "adverse effects of treatment are an uncommon cause 
of poor compliance". 46 The same Hong Kong group found in a subsequent study that 
only 5% of patients required treatment modification as a result of significant adverse 
effects of the drugs - again no mention was made of nonadherence. 14 A Brazilian study 
of twice weekly versus daily therapy found that permanent discontinuation of therapy 
due to adverse effects occurred in less than 1 % of patients on each regimen. 10 
Westaway and Wessie report on care-givers' perceptions of problems in giving TB 
treatment to children, but none were related to side-effects of medication.94 
4) Demographic characteristics. 
As already seen (Sumartojo79), little can be altered here. It seems that these factors 
have more of an impact on utilisation of health services in the first place, rather than 
on adherence to treatment. b 
5) The physician-patient interaction. 
In terms of how tuberculosis services are structured worldwide and for the purposes of 
this discussion, read this as: The service-patient interaction. This has been found to be 
consistently positively associated with adherence, and is highly responsive to 
intervention. Two aspects of the interaction carry importance: effectiveness of 
communication and the emotional impact. 
a) Effectiveness of communication: 
Good recall of information about the illness, accurate recollection of the physician's 
expectations and increased knowledge of the prescribed regimen all increase 
b Adherence viewed in its broadest sense - why people choose certain services 
like traditional healers in preference to others, or choose not to utilise any service, or 
choose to come only at a late stage - was beyond the scope of this thesis. 
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adherence. In addition, a long established relationship with a specific physician also 
gives "unusually" high adherence rates. Sbarbaro underlines this: "I am deeply 
convinced that only through a relationship with a health professional truly concerned 
with the patient's entire health ... can we hope to influence a patient's health 
behaviour". 68 Sumartojo states that outreach workers also independently improve 
adherence. 79 Comprehensive services and thorough case management have been 
shown by Werhane et al in 1989 and by Curry in 1969 to have a potent positive effect 
on adherence 79 All these contribute to effective overall communication. A recent study 
conducted by Dick in Cape Town has shown that where tuberculosis nurses were 
trained in communication skills, the risk of nonadherence in their clients was 
significantly reduced. 26 This intervention also led to increased motivation and 
enthusiasm in the staff, factors which are associated with improved treatment 
outcomes. 
b) Emotional impact: 
When patients feel satisfied with the interaction, when their expectations have been 
met, when they feel accepted, appreciated and respected, then they adhere better to 
treatment. In contrast, excessive waiting time - indicative of low respect - is associated 
with poor adherence and high dropout. In adult settings, friendliness and a relaxed 
atmosphere are not necessarily conducive to adherence. But antagonism, tension and 
confrontation are predictive of nonadherence. In paediatric settings, when mothers 
believed they were viewed as "good mothers", their adherence in giving their childrens' 
medication was enhanced. 40 It was lessened if they sensed unfriendliness, hostility, 
tension or punitiveness. 
In summary then, the best predictor of adherence is the client's own history of 
adherence. The best interventions for ensuring adherence are a) supervision of 
therapy, and b) quality services which satisfy both the medical and emotional 
expectations of the clients. A surprising finding was that medication side-effects play 
little part in nonadherence. 
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2.3.2 The scope of the problem: 
Tuberculosis aside for a moment, there are a few notable studies which depict the 
magnitude of adherence difficulties across the board of medical diseases: 1) Marston 
in 1970 surveyed 33 carefully conducted studies, covering a wide range of medical 
problems, and found a median of 43% of patients nonadherent.55 2) Macharia in 1992, 
using meta-analysis of randomised trials, showed an average appointment-keeping rate 
of merely 58%.54 Nonadherence is thus not disease-specific for tuberculosis. 
For tuberculosis, the picture is discouraging. In developing countries, the proportion of 
patients with active disease who complete therapy under standard conditions is as little 
as 20 - 40%. 56 In the USA, the CDC reports that only 75% of patients with active 
tuberculosis actually complete the usual 6 month therapy inside 12 months. 13 Among 
those who are homeless and alcoholic, nonadherence approaches 90%. 79 
The South African situation 
No figures on adherence to tuberculosis therapy are specifically and routinely 
published by the Department of Health in South Africa. The 1992 Tuberculosis Control 
Programme is credited with a 78% cure rate. 23 This is based on the "old South Africa" 
boundaries - the so-called homelands were excluded. The abscondment rate was 17% 
and the death rate 5%. 
Three studies are cited by Strebel and Seager in "A Century of Tuberculosis: South 
African perspectives" edited by Coovadia and Benatar. 19 These will be used to illustrate 
some of the points made below in how adherence is measured: 
1) Soweto figures from 1978 show that only 28% had received 80% or more of 
the required therapy by one year. 66 
2) In the Ciskei region, a Hewu study showed that 75% of patients placed on 
daily supervised therapy completed 80% of their doses. 20 
3) A cross-sectional study in the Western Cape found that 82.5% of patients had 
completed more than 75% of their treatment by the survey date.2 
A recent study from Kwazulu/Natal - Hlabisa Health Ward - showed a very high rate of 
adherence, measured by completion rates, where 83% completed therapy. 95 This was 
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achieved using twice weekly ambulatory therapy, and success was attributed to many 
different modalities of treatment sites and supervisors used, as well as regular audit 
and feedback to the team involved. 
The report of the Western Cape's Strategic Management Team: Task Force on 
Tuberculosis of December 1994 showed that 19% of the patients fail to complete 80% 
of their treatment 37 But the report also states that the data are not accurate. More 
accurate data for Cape Town by Dick show that only about 60% (56.4%, 62% and 
58.3% in 3 different studies) of patients complete 75% - 80% or more of their 
prescribed tuberculosis medication. 26 The Western Cape Regional Services Council 
(now the Cape Metropolitan Council), which carries the single largest annual caseload 
of tuberculosis of any local authority in South Africa, reports that in 1993 the rate of 
patients completing treatment was 63%, whereas the treatment interruption rate was 
21 %. 81 These data were collected longitudinally for each patient. 
2.3.3 Measuring adherence 
There is no gold standard for measuring adherence, either in tuberculosis or 
generally79 · 88· 90. There are two broad ways of quantifying the phenomenon of 
adherence in tuberculosis, the first being categoric and the second numeric: 
Rate 
Completion or dropout rate 
Adherence rate 
Definition 
(No. so categorised/ No. enrolled) x 100% 
(Doses taken/ Doses prescribed) x 100% 
Note: The completion or dropout rate can also be found expressed as adherer, 
complier, intermediate adherer, nonadherer, defaulter, absconder or delinquent rates 
as the case may be. Adherence can be studied as a continuous variable without 
categorising patients, but in most practical settings and research studies categorical 
classification is utilised. 
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Completion or dropout rates: 
Treatment completion rates: This measure can be used in the case of tuberculosis 
because there is an endpoint definable at the start of therapy. In the case of a number 
of chronic diseases (adult asthma, diabetes, epilepsy or hypertension) treatment could 
be lifelong, and this measure would not be applicable. The definition is the number of 
patients completing treatment or discharged-as-cured over the number of patients 
starting. This measure could however be time bound, eg. measuring the percentage 
completing a required therapy by 6 months, or 12 months as in the Soweto study 
above. 66 Adherer rates: This is the number of patients adherent (eg. 75% or better 
adherence) over the total on treatment. The results from Hewu above are an example 
of this measure. 20 It is similar to the completion rate, but differs from the adherence 
rate, below. DelinquenU defaulter/ dropout rates are also reported in trials as an 
indication of the adherence to therapy. This is the number of patients who at one or 
other time during their treatment were nonadherent (various definitions are operative 
here, eg. missed 14 or more consecutive days on treatment, or whose monthly rate was 
<80%, were defaulting (missed >2 months of treatment) or who dropped out altogether. 
This must be seen as invaluable extra information because it alters the power of the 
conclusions or recommendations of any particular work. 
Adherence rates: (doses taken/prescribed x 100%) 
This should be measured longitudinally, not cross-sectionally, and the intention-to-treat 
(or inception cohort) method should be used. 102 If cross-sectional methodology is used, 
results could be skewed to reflect spuriously greater adherence rates. The intention-to-
treat method uses as denominator all those who were initially enrolled, not only the 
treatment completers. It analyses the cohort by intention to treat. The systematic loss 
to analysis of nonadherents cannot otherwise be overcome by statistical manoevres. 40 
The method entails monitoring the adherence of each patient longitudinally from the 
commencement of therapy until the point of discontinuation. 
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The adherence rate which ensures cure has never been scientifically determined, and 
so the definitions of nonadherence that are used differ. Few authors actually give their 
definitions of nonadherence, and if they do it is often just en passant. Because "count-
compliance" is often used, and because dose-timing information is not available, it is 
scientifically impossible to correlate therapeutic outcome with adherence. 88 Thus 
definitions which use a cut-off point are at this stage still arbitrary, but there are no 
objective data to recommend one cut-point above another. Possible ways of addressing 
this lack are:4° 
Biologically, where nonadherence is defined as falling short of the point where 
the desired therapeutic outcome is unlikely to occur. 26 
Epidemiologically, where nonadherence is defined in terms of Tuberculosis 
Control Programme objectives. 15 
Statistically, where nonadherence is related to a measure of central tendency, 
eg. the median. 26 
Chaulet states that the failure rate of regimens increases when over 25% of doses are 
omitted. 15 This is probably the origin for the 75% cut-off which is often used. 
The two adjacent large local authorities in Cape Town have thusfar used different 
definitions. The Cape Town City Council Health Service has used a level of 80% doses 
taken/doses prescribed as the categorical cut-off, whereas the Western Cape Regional 
Services Council (now the Cape Metropolitan Council) has used 75%. The new South 
African National Tuberculosis Register system surprisingly uses 67% as the cut-off for 
treatment interruption - 2 months off treatment over the 6 month period is considered 
a "treatment interruption". 
Of the numerator and denominator in the above equation, the prescribed doses 
(denominator) is the easier to obtain: from the patient's notes, study protocol or 
standard treatment regimen of the Tuberculosis Control Programme. The doses 
actually taken (numerator) is more difficult. Haynes, Taylor and Sackett40 divide the 
measures used to monitor or estimate the actual doses - and thus adherence rates -
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into 4 categories of decreasing credibility: 
a) Objective direct and longitudinal measures 
b) Immediate direct measures 
c) Objective indirect measures 
d) Subjective indirect measures. 
a) Objective direct and longitudinal measures 
This category is the only one viewed by Vander Stichele90 as suitable for measuring 
compliance in clinical trials. Such measures are 1) devices and 2) markers or tracer 
substances. 
1) Devices rely on mechanical events to register a pill taking event. The original (all-disease) prototype was developed by Moulding in 1962 for the very purpose of 
monitoring compliance in tuberculosis. However, such gadgets have been largely 
ignored by the tuberculosis experts since. 67 The most exciting modern devices are 
electronic recording systems: microelectronic circuits contained in the cap of a classical drug container to record the time of opening and closing of the container, thus storing data on times and dates. Data can be fed into a microcomputer by plugging a cable into 
a tiny female jack on the cap, and then processed for analysis. 90 This gives 
unprecedented feedback to the health care providers, both for the individual patient 
and for programme evaluation. 
2) Markers are "substances, which are co-formulated with study drug and placebo to measure patient compliance with drug therapy". 90 These include radioactive 
substances, inert molecules, stable isotopes (notably deuterium oxide - heavy water) 
and pharmacological substances like low dose phenobarbital or digoxin.88· 90 They work 
on much the same principle as HbA1 c (in diabetes, albeit inversely), in that the level 
of adherence to therapy is related to the blood level of the identified marker. Some 
markers can also theoretically measure the chronology of dosing. 
b} Immediate direct measures, eg. blood levels of the drug, or urine tracer tests. In tuberculosis, this would usually be an INH urine test, a commercially available paper 
strip test. The colorimetric Potts-Cozart test for INH has been used by the State of Arkansas, USA, in preference to the commoner INH urine tests. 69 The problem with this 
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method is that it often measures "white coat compliance", or the adherence in the 
immediate pre-appointment period. This difficulty can be circumvented by random visits 
to the patient to obtain specimens. 
c) Objective indirect measures, eg. Directly observed therapy, count compliance, 
pill count or attendance for prescription refill. The last two can unfortunately easily be 
distorted by the patient discarding leftover tablets. This is the commonest method used 
operationally by the tuberculosis services. Also included in this category by Haynes, 
Taylor and Sackett is therapeutic outcome - a biological measure of compliance. 
d} Subjective measures, eg. interview of the patient, the patient's family or of the 
clinician. That clinicians cannot subjectively accurately identify those nonadherent has 
been emphasized by a number of authors. 40• 78· 79 This measure is usually the least 
reliable. Some of the early writers on the subject believe, however, that a well 
conducted interview is a better means of obtaining the adherence rate than pill count. 88 
This art was termed clinimetrics. 
Research quoted by Sumartojo ag:·ees with the above weighting. Stone78 states that 
estimates of the degree of adherence seem to be negatively correlated with the 
objectivity of the method! 
Sumartojo suggests that probably the best approach to measure and express 
adherence would be to use multiple measures. Vander Stichele has suggested the 
development of an adherence index to reflect the vagaries of complex patient 
behaviour. 90 Expressing adherence as continuous longitudinal data and a statistical 
reporting format might also become the standard. 
Summarising adherence rate measurement then, one can conclude that no single 
adherence measure is sufficient to tell the full story of a complex interaction, and that 
accurate adherence data are not easily obtained. 
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Methods used locally 
Dick 26 in her PhD thesis "Adherence to antituberculosis therapy in Cape Town" utilised 
count compliance with the categorical cut-off as 75% doses taken/doses prescribed, 
employing the inception cohort or intention-to-treat method. Dick categorised the 
patients as adherents, defaulters and erratic. Periods of no treatment in weeks were 
reported, as well as average dose units per week. 
2.3.4 Improvement strategies/ Management of nonadherence. 
In general, the literature on nonadherence is not well described in this regard. 
Reichman outlines a number of methods for improving adherence and at the same time 
intimates a need for international collaboration on programmes to enhance 
adherence. 63 The methods were directly observed therapy, incentives and enablers, 
fixed-dose combination pills, patient education, appointment reminders, and 
comprehensive services. I could find no easy step-by-step measures or "recipes" to 
manage nonadherence as it occurs in the clinics. There were a few guidelines, however 
in the following reports: 
1) The American Lung Association of South Carolina has outlined a number of 
methods used to improve adherence with therapy, called "Enablers and lncentives"27. 
Enablers are indirect measures that help the patient to more readily complete the 
therapy. Incentives are large or small, and can be food, goods or services. (The 
distinction between enablers and incentives was not clear.) They are aimed at getting 
the client to take medicine and keep appointments. Some examples of enablers and 
incentives are food, clothing, automotive accessories (eg. motor oil), fishing supplies, 
household cooking utensils, general services (eg. laundry), transportation, specials for 
holidays (eg. Thanksgiving hams), help with children, personal care and flowers for the 
garden. 
2) The South Carolina Department of Health and Environmental Control and the 
New York City Department of Health have attempted to improve adherence using many 
strategies, often combined 11 They are a mixture of "carrot" and "stick": apart from 
enablers and incentives mentioned above, they also use directly observed therapy (DOT), court-ordered DOT and even commitment for in-patient management for 
recalcitrant nonadherers. 
18 
However, in light of the review by Stone summarised above on page 9, a more 
perspicacious and rational approach should be that of Rouillon,64 who sees a default 
as "an omission on the part of the patient or the services, an omission which 
necessitates a corrective intervention, in the interests of the patient and/or in those of 
the community", again de-emphasising a convergence on the patient. The primary 
focus of action following nonadherence is then not solely on the patient but includes 
the services and the community. She makes the point that preventive management of 
adherence is the most important, and that all 5 levels of those involved need to be 
proactively motivated: Politicians, legislators and leaders; planners; doctors and staff 
of the public health services; the community; and lastly, patients. The most important 
group to be motivated, she states, are the staff who carry out the Tuberculosis Control 
Programmes, because their efficiency and attitudes have a direct effect on the quality 
of the services, on their delivery and on the patients themselves. The problem with this 
approach is that these staff are often reluctant to change their ways. In the words of 
Rubel and Garro: "Because delivery of health care is governed by time-honored 
traditions learned during professional training and supported by programmatic norms, 
however, efforts to modify attitudes and behavior of clinical staff often meet with 
resistance." 65 
2.3.5 Summary 
In Cape Town, an area with very high incidence rates of both adult and childhood 
tuberculosis, the extent of nonadherence to tuberculosis multi-drug therapy is high -
about 40%. Accurate data on adherence rates are not easily obtained, and objective 
indirect methods have thusfar been employed. The best predictor of adherence is the 
patient's own treatment record, and the best methods for improving adherence are 
supervision of therapy and satisfying the patients' emotional and medical needs. More 
emphasis should be placed on preventive management of nonadherence by training 
and motivating the staff in the clinics, difficult as this may be. 
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2.4 Literature on intermittent chemotherapy for tuberculosis 
The first consideration should be to theoretical models. Mitchison and Dickinson did 
experimental laboratory work on this subject in the 1960's on guinea pigs. 58 The work 
was then summr -;c;ed again by Mitchison, and the verdicts for the various drugs were 
as follows: 57 
lsoniazid 
Rifampicin 
Pyrazinamide 
Ethambutol 
Streptomycin 
Ethionamide 
Thiacetazone 
Effective in dose intervals up to 4 days; 8 days too long. 
More effective when given intermittently. 
Similar duration of sterilising activity from 1 and 4 day exposure. 
More effective when given intermittently. 
Little change in activity as doses became more intermittent. 
Little change in activity as doses became more intermittent. 
Much less effective if given intermittently. 
Intermittent therapy for the main drugs clearly works in vitro. With isoniazid (INH), no 
regrowth occurs between doses if spaced over 4 days, but 8 days seems too long a period. This is borne out by clinical studies described in the following section, which proved that once weekly therapy was ineffective. Rifampicin is more effective intermittently because the mycobacterium is much more susceptible during the growth phase than it is during the preceding lag phase. The mechanisms for pyrazinamide and 
ethambutol are unclear. Pyrazinamide may inhibit the organism to then be killed by host defences. 
2.4.1 Intermittent chemotherapy for tuberculosis - adults 
Case study research using intermittent therapy for tuberculosis started in 1953, just a few years after the introduction of isoniazid. In summary, the history of the advances in intermittent therapy mirror the advances in the usual daily therapy. The main 
advances ( simplified) were3 
a) the move away from monotherapy (in the 1950 and 60s}, 
b) the demonstrated effectiveness of rifampicin in 1973, 
c) the use of pyrazinamide as a first-line agent and the concept of Short Course 
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Chemotherapy (1974-1981). 
These advances were mainly informed by 1) high resistance rates following 
monotherapy 2) early and sustained sterilisation and 3) low relapse rates. 32 
Allied to these advances was the use of intermittent therapy for the continuation phase 
of therapy, following a so-called initial intensive phase, which was based on the 
experimental work of Mitchison. Current thinking is that fully intermittent therapy is as 
effective as daily therapy, 11 provided that an initial intensive daily phase is desirable 
and that 4 drugs should be used. There is a difference in opinion as to whether thrice 
or twice weekly therapy is better. The WHO favours thrice weekly, 99 whereas the CDC favours twice weekly. 12· 13 Once weekly therapy has been proven to be ineffective. 72 
The trends and advances in the scientific experience with this form of treatment in 
adults are set out in Table A below. For tables A, 8 and C the standard abbreviated 
notation for tuberculosis regimens is used. There are slight variations in how this 
notation is used. A subscript following the drug abbreviation indicates the frequency of intermittent dosing. For some writers a subscript covers all preceding letters, but most 
use brackets or a subscript immediately following the each letter.c The latter method is 
used in this thesis because it can describe the treatment regimen more accurately. 
Studies of the 1950s and 1960s 
These are characterised by mono- and dual-drug therapy. Monotherapy fell out of favour because of rising resistance rates as the therapy progressed. Intermittent 
therapy twice weekly was shown to be as effective as daily therapy, but a dosing frequency of once weekly was ineffective. 
The first large controlled follow-up study was performed in India by the Madras Tuberculosis Chemotherapy Centre, which showed that twice weekly supervised therapy was at least as effective as daily self-supervised therapy. 84 Although the initial 
c As illustration, a study of tuberculosis in childhood by Varudkar92 has been differently reported as 6 H3R3E3 by Starke,77 and 6 HRf:ii by the original article, which assumed that the subscript covered all 3 preceding letters. 
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treatment duration was 12 months, there was still residual cavitation present at the end 
of treatment in a large number of subjects (31 %), and these were continued with isoniazid monotherapy for 6 or 12 months. 61 A "logical consequence" study (as it was termed) done by the same group found that once weekly therapy was ineffective.85 
Studies of the 1970s 
There were two main advances in this period. The first was establishing the safety of 
rifampicin in intermittent therapy. While the Madras Tuberculosis Chemotherapy Centre 
was continuing with good studies on twice weekly therapy without rifampicin, others 
were starting to include rifampicin in treatment trials. The Poole study of 1971, which 
used a rifampicin dose of 1200mg in the intermittent phase, was terminated because 
of significant toxic effects and development of antibodies to rifampicin. 60 A later study -Fox et al of 1977 - used inter alia 900mg of rifampicin twice and once weekly, but found that a) once weekly therapy was ineffective and b) there were significant toxic effects 
with once weekly 900mg rifampicin. 71 .72 Thus rifampicin gained a reputation of being toxic. The study of Mitchison, Allen et al in Hong Kong in 1978, however, laid to rest the 
spectre of immunologic reactions to rifampicin, with few incidents either of the "flu" 
syndrome or rifampicin dependent antibodies. 43 Outt's study of 1979, using a lower dose of 600mg of rifampicin, found that it was effective at this lower dose and also that it carried no toxic effects. 29 
The second advance was the use of pyrazinamide as a first-line agent. The trial of Mitchison, Allen et al in Hong Kong cited above also made the significant advance of 
using pyrazinamide with rifampicin as a first line agent and showed its worth a) in improved early sterilisation rates and b) in preventing relapse after therapy. 43 Pyrazinamide was shown to outpertorm both streptomycin and ethambutol. 
Studies of the 1980s 
These studies served to confirm that pyrazinamide should be used as a first-line agent 
as it gave lower relapse rates, and that intermittent therapy - whether fully or only partially intermittent - was indeed successful even over 6 months. Additionally, only 2 drugs were used for the "continuation phase" (after the "intensive phase" of the first 1 -
22 
2 months). 
Snider's study of 1982 was noteworthy in that the total duration of therapy was 
successfully shortened to 6 months using intermittent therapy. 75 Fully 29% failed to 
c.omplete their therapy, but those with good adherence had early sterilisation and 0% 
relapse. The Singapore study of Fox and others, using 1 - 2 months of daily therapy 
and 4 - 5 months of thrice weekly dosing, showed a combined failure and relapse rate 
of <2% over 24 months' of follow-up, including those with drug-resistant bacilli. 73 This 
controlled trial showed the effectiveness of a regimen with just 3 drugs (isoniazid, 
rifampicin and pyrazinamide) in the initial phase, followed by isoniazid and rifampicin 
only, given intennittently. However, the regimen with 4 drugs for 2 months in the initial 
phase had the highest early sterilising activity. In Hong Kong, a study by Allen, Chan 
et al used 4 fully intermittent therapy regimens and 1 fully daily regimen for 6 months 
to work out optimal combinations of drugs. 44 The significant finding here was that the 
recurrence rate was three times greater with a regimen containing no pyrazinamide. 
Castelo et al (1989) showed that even where "skid-row'' patients were not excluded, a 
partially intennittent regimen was effective in a clinic-based use-effectiveness setting. 10 
Studies in the 1990s 
The main advance was calculating the optimal duration of pyrazinamide treatment. 
Fredlund of South Africa showed that fully intermittent twice weekly therapy using 4 
drugs was as effective on an out-patient therapy as it was for in-patients.35 The out-
patient regimen used ethambutol as the fourth drug, in addition to the usual rifampicin, 
isoniazid and pyrazinamide. In-patients were given streptomycin as the fourth drug. 
Girling, Chan et al of Hong Kong did a detailed clinical trial with out-patient fully 
intennittent thrice-weekly therapy. 47 All got isoniazid and rifampicin for 6 months, and 
streptomycin for 4 months. The different groups were given 2, 4 and 6 months of pyrazinamide. An additional group was given no streptomycin, but 6 months of 
pyrazinamide. This study showed that even with fully intermittent therapy, pyrazinamide 
can be given only for the first 2 months, and also argued that a fourth drug is necessary 
in the initial phase if the regimen is fully intermittent. In the presence of isoniazid 
23 
resistance, there was however an advantage in giving pyrazinamide for the whole 6 
month period. 
In summary, intermittent therapy was found to be as effective as daily treatment for 
uncomplicated pulmonary tuberculosis in adults. 
24 
TA
B
LE
 A
: 
Tr
en
ds
 a
n
d 
a
dv
an
ce
s 
in
 in
te
rm
itt
en
t t
ub
er
cu
lo
si
s 
tr
ea
tm
en
t 
in
 a
du
lts
 
ST
UD
Y.
 Y
EA
R
 A
ND
 L
O
CA
TI
O
N 
Fr
im
od
t-M
ol
le
r e
t a
l,3
6 
19
53
 
Ka
tz
 e
t a
 I, 5
0 
19
54
/5
 
Ty
rre
ll,
87
 1
95
6 
H
ol
m
es
 e
t a
l,4
1 
19
62
 
M
ad
ra
s 
TB
 C
en
tre
 ,84
 
19
63
 
In
di
a 
Po
ol
e 
et
 a
l,6
0 
19
71
 
En
gl
an
d 
M
en
on
, T
rip
at
hy
 e
t a
l,8
6 
19
73
 
In
di
a 
N
U
M
BE
R
 
91
 
29
 
16
5 
49
 
24
7 
R
EG
IM
EN
 
3H
2 
v 
3H
 
S?
H2
 
V
H
S,
 
S 2
H 2
,
 
In
-p
at
ie
nt
 
S 2
H
2,
 
O
ut
-p
at
ie
nt
 
3H
1 
o
n
ly
 
12
PH
 
12
H
2S
, 
3H
R
S/
(15
)H
2R
, 
0.
5P
H
S/
12
PH
 
0.
5P
H
S/
12
P 2
H
2 
R
ES
UL
TS
 
Si
m
ila
r C
XR
 fi
nd
in
gs
 a
t 1
2 
w
e
e
ks
 
In
fe
rio
r r
e
su
lts
 w
ith
 fu
lly
 tw
ic
e 
w
e
e
kl
y 
th
er
ap
y.
 
78
%
 fa
vo
ur
ab
le
 o
u
tc
om
e 
80
%
 fa
vo
ur
ab
le
 o
u
tc
om
e 
O
nl
y 2
 b
ec
am
e 
cu
ltu
re
 n
e
ga
tiv
e.
 
1 
di
ed
; 8
9%
 n
e
ga
tiv
e 
a
t 9
 m
o
n
th
s;
 4
.4
%
 r
e
la
ps
e 
2 
di
ed
; 9
3%
 n
e
ga
tiv
e 
a
t 9
 m
o
n
th
s;
 6
.3
%
 r
e
la
ps
e 
Tr
ia
l t
er
m
in
at
ed
 -
se
e
 c
o
m
m
e
n
ta
ry
 
87
%
 n
e
ga
tiv
e 
a
t 1
2 
m
o
n
th
s,
 s
e
lf 
su
pe
rv
is
ed
 
88
%
 n
e
ga
tiv
e 
at
 1
2 
m
o
n
th
s,
 c
lin
ic
 s
u
pe
rv
is
ed
 
N
ot
at
io
n:
 E
 =
 e
th
am
bu
to
l; 
H
 =
 IN
H;
 P
 =
 P
AS
; R
 =
 rif
am
pi
cin
; S
 =
 
st
re
pt
om
yc
in
; Z
 =
 py
ra
zi
na
m
id
e.
 
2H
R
Z/
4H
2R
2 
m
e
a
n
s 
2 
m
o
n
th
s 
o
f H
R
Z 
fo
llo
w
ed
 b
y 
( /
) 4
 m
o
n
th
s 
o
f H
an
d 
R,
 b
ot
h 
2 
tim
es
 a
 w
e
e
k.
 I
f n
o 
fig
ur
e 
fo
llo
w
s 
th
e 
le
tte
r, 
da
ily
 tr
ea
tm
en
t i
s 
a
ss
u
m
e
d.
 
NB
. T
he
 d
et
ai
ls
 o
f s
o
m
e
 o
f t
he
 e
a
rli
er
 s
tu
di
es
 a
re
 n
o
t a
lw
ay
s 
cl
ea
r, 
a
n
d 
th
us
 n
o
t s
ho
w
n.
 O
ut
co
m
e 
m
e
a
su
re
s 
in 
th
e 
va
rio
us
 s
tu
di
es
 d
iff
er
ed
. 
25
 
TA
B
LE
 A
 (c
on
tin
ue
d)
: T
re
nd
s 
an
d 
a
dv
an
ce
s 
in
 in
te
rm
itt
en
t t
ub
er
cu
lo
si
s 
tr
ea
tm
en
t i
n 
a
du
lts
 
ST
UD
Y.
 Y
EA
R
 A
ND
 L
O
CA
TI
O
N 
Fo
x 
e
t a
l .7
1 
72
 1
97
7 
Si
ng
ap
or
e 
M
itc
hi
so
n.
 A
lle
n 
e
t a
l,"1
3 
19
78
 
H
on
g 
Ko
ng
 
D
ut
t e
t a
l ,2
9 
19
79
 
Ar
ka
ns
as
, U
SA
 
N
U
M
BE
R 
48
1 
68
0 
31
5 
11
9 
R
EG
IM
EN
 
0.
5S
H
R
/1
2-
18
H
2R
2 
0.
5S
H
R
/1
2-
18
H
1R
1 
6S
H
R
 
2S
H
R
Z/
4-
6S
2H
2Z
2 
2S
H
R
E/
4-
6S
2H
2E
2 
4S
3H
3R
3Z
i2
-4
S
2H
2Z
2 
1 H
R
/8
H
2R
2 
o
n
ly
 
2H
R
ZS
/4
H
2
R
2 
o
n
ly
 
R
ES
U
LT
S 
N
o 
re
la
ps
es
 in
 1
8 
m
o
n
th
 g
ro
up
s 
N
o 
re
la
ps
es
 in
 1
8 
m
o
n
th
 g
ro
up
s 
4%
 r
e
la
ps
e 
by
 6
 m
o
n
th
s 
3%
 r
e
la
ps
e 
by
 6
 m
o
n
th
s 
-
Th
is
 re
gi
m
en
 c
o
n
ta
in
ed
 n
o
 Z
, a
n
d 
ha
d 
a
 1
9%
 r
e
la
ps
e 
ra
te
 b
y 
6 
m
o
n
th
s 
5%
 r
e
la
ps
e 
by
 6
 m
o
n
th
s 
95
%
 b
ac
te
rio
lo
gi
ca
lly
 n
e
ga
tiv
e 
a
t 3
 m
o
n
th
s;
 1
0 
fa
ilu
re
s;
 1
 re
la
ps
e.
 
29
%
 fa
ile
d 
to
 c
o
m
pl
et
e 
th
er
ap
y 
Sn
id
er
 e
t a
l,7
"
 
19
82
 
Po
la
nd
 
71
 %
 c
o
m
pl
et
ed
 th
er
ap
y:
 1
00
%
 b
ac
te
rio
lo
gi
ca
lly
 n
e
ga
tiv
e 
a
t 3
 m
o
n
th
s;
 n
o
 r
e
la
ps
es
 
Fo
x 
e
t a
l,7
3 
19
85
 
Si
ng
ap
or
e 
42
0 
2H
R
ZS
/4
H
3R
3 
1 H
RZ
S1
5H
3R
3 
2H
R
Z/
4H
3R
3 
1 
Ba
ct
er
io
lo
gi
ca
l f
ai
lu
re
; 
1 
re
la
ps
e 
4 
re
la
ps
es
, i
nc
lu
di
ng
 3
 w
ith
 d
ru
g-
re
si
st
an
ce
 
1 
re
la
ps
e 
N
ot
at
io
n:
 E
 =
 
e
th
am
bu
to
l; 
H
 =
 
IN
H
; P
 =
 
PA
S;
 R
 =
 
rif
am
pi
ci
n;
 S
 =
 
st
re
pt
om
yc
in
; Z
 =
 
py
ra
zi
na
m
id
e.
 
2H
R
Z/
4H
2R
2 
m
e
a
n
s 
2 
m
o
n
th
s 
o
f H
R
Z 
fo
llo
w
ed
 b
y 
( /
) 4
 m
o
n
th
s 
o
f H
an
d 
R,
 b
ot
h 
2 
tim
es
 a
 w
e
e
k.
 I
f n
o
 fi
gu
re
 fo
llo
w
s 
th
e 
le
tte
r, 
da
ily
 tr
ea
tm
en
t i
s 
a
ss
u
m
e
d.
 
26
 
TA
B
LE
 A
 (c
on
tin
ue
d)
: T
re
nd
s 
an
d 
a
dv
an
ce
s 
in
 in
te
rm
itt
en
t t
ub
er
cu
lo
si
s 
tr
ea
tm
en
t 
in
 a
du
lts
 
ST
UD
Y,
 Y
EA
R
 A
ND
 L
O
CA
TI
O
N 
Al
le
n,
 C
ha
n 
e
t a
l,4
4 
19
87
 
H
on
g 
Ko
ng
 
Ca
st
el
o 
e
t a
l,1
0 
19
89
 
Br
az
il 
Fr
ed
lu
nd
,35
 1
99
0 
So
ut
h 
Af
ric
a 
G
irl
in
g,
 C
ha
n 
et
 a
l,4
7 
19
91
 
H
on
g 
Ko
ng
 
NU
M
BE
R 
12
07
 
66
7 
37
3 
13
86
 
R
EG
IM
EN
 
6(
HR
2S
E)
3 
6(
HR
2S
) 3 
6(
HR
2E
) 3 
6H
R
2E
 
6(
HR
SE
) 3 
2H
R
Z/
4H
R
 
2H
R
Z/
4H
2R
2 
6(
HR
2S
h 
6(
HR
2E
) 2 
4H
3 
R
3 
S
i2
H
3 
R
3 
+
 2
2 3
 
4H
3 
R 3
 S
3/2
H
3 
R
3 
+
 4
2 3
 
4H
3 
R
3 
S
)2
H 3
 R
3 
+
 6
2 3
 
6H
3 
R
3 
2 3
 
R
ES
UL
TS
 
-
Th
es
e 
to
p 
4 
re
gi
m
en
s 
ha
d 
a
 3
.4
%
 c
o
m
bi
ne
d 
re
cu
rr
e
n
ce
 r
a
te
 
-
Th
is
 re
gi
m
en
, w
ith
 n
o
 p
yr
az
in
am
id
e,
 h
ad
 a
 1
0.
3%
 re
cu
rr
e
n
ce
 r
a
te
 
17
 d
ie
d;
 7
%
 r
e
la
ps
e 
10
 d
ie
d;
 4
%
 r
e
la
ps
e 
In
-p
at
ie
nt
s.
 2
 d
ie
d;
 4
.3
%
 r
e
la
ps
e 
O
ut
-p
at
ie
nt
s.
 2
 d
ie
d;
 4
.7
%
 r
e
la
ps
e 
N
o 
fa
ilu
re
s;
 3
%
 r
e
la
ps
e 
ra
te
 
N
o 
fa
ilu
re
s;
 5
%
 r
e
la
ps
e 
ra
te
 
N
o 
fa
ilu
re
s;
 3
%
 r
e
la
ps
e 
ra
te
 
Ba
ct
er
io
lo
gi
c 
fa
ilu
re
 in
 2
%
 (p
<0
.00
5 v
 o
th
er
 re
gi
m
en
s) 
N
ot
at
io
n:
 E
 =
 e
th
am
bu
to
l; 
H
 =
 
IN
H
; P
 =
 P
AS
; R
 =
 
rif
am
pi
ci
n;
 S
 =
 s
tre
pt
om
yc
in
; 2
 =
 py
ra
zi
na
m
id
e.
 
2H
R
Z/
4H
2R
2 
m
e
a
n
s 
2 
m
o
n
th
s 
o
f H
R
Z 
fo
llo
w
ed
 b
y 
(I
) 4
 m
o
n
th
s 
o
f H
an
d 
R,
 b
ot
h 
2 
tim
es
 a
 w
e
e
k.
 I
f n
o 
fig
ur
e 
fo
llo
w
s 
th
e 
le
tte
r, 
da
ily
 tr
ea
tm
en
t i
s 
a
ss
u
m
e
d.
 
27
 
2.4.2 Intermittent chemotherapy for tuberculosis - children 
In contrast to adult studies where intermittent therapy largely kept step with the advances in daily therapy, research in the intermittent treatment of children started only in the 1980s, sparked by articles by Fox, 32 Smith74 and possibly Kendig. 51 An excellent 
review of the entire subject of childhood tuberculosis therapy is provided by Starke. 77 Generally, the findings are similar to those in adults, i.e. the results of intermittent treatment are equal to daily treatment. It must be said, however, that the adult studies have been better conducted (much "tighter") scientifically, with larger numbers and better follow-up. The reason for this might be that endpoints in the treatment of childhood tuberculosis are more difficult to identify. By 1982 there were only 3 published papers on short course chemotherapy in children, 74 let alone intermittent 
short course chemotherapy. Trends and advances in the published studies are summarised in Table B. 
The first study on intermittent therapy in children was from Chile. 48 The two groups 
were, however, not strictly comparable as their entry criteria as well as treatment 
regimens differed - those who were smear positive were put onto 4 drug therapy; those culture-only positive got 3 drug therapy. Nevertheless, satisfactory results were obtained. 
Abernathy 1 reported in 1983 on a group of consecutively enrolled children put onto a 9 month regimen. Only the first month was daily therapy, with the months thereafter being twice weekly therapy only. "Excellent results" were reported by the researchers themselves, but no data were offered. It appears that all children were in fact cured by 9 months, although not unexpectedly, hilar adenopathy persisted on radiographs for 2 to 3 years. The first reported fully intermittent trial in children came from India in 1985.92 There was a reported "excellent reponse" in 86% of the cases; again the claim was not further substantiated by statistics. 
Biddulph's trial was notable for its sheer size and also for the high dropout rate: only 373 (58%) completed the 6 month course, and the follow-up rate was 34.9% of the inception cohort. 7•8 This study is said to have established the safety and efficacy of 
28 
short-course chemotherapy in children, but the claim cannot be accurate in view of the 
high dropout rate. 
The small StarkefT aylor Watts study had no failures, relapses or toxicity. 76 In the 
Khubchandani study, three deaths occurred but it was not stated in which treatment 
group/s they occurred. 52 An interesting finding was that there was more toxicity in the 
fully daily group. 
The Kumar trial was the first well-researched and documented study on fully intermittent 
therapy in childhood tuberculosis. 53 Both pulmonary tuberculosis and lymphadenitis 
tuberculosis were studied, making the numbers in each group small - approximately 20. 
Asymptomatic primary complex cases were excluded, and this might account for the 
relatively high death rate of 2.6%. Results obtained for the 2 groups were comparable. 
In summary, despite the drawbacks mentioned, these studies have suggested that 
intermittent therapy is as efficacious as daily therapy in treating childhood tuberculosis. 
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2.5 Studies on adherence in childhood tuberculosis 
Studies which addressed adherence are chronologically summarised in Table C. 
Only 2 studies, those by Dick26 and by Oviawe and Ojemudia59, dealt specifically with 
adherence. For the purposes of investigating adherence on different drug regimens, 
however, the study by Seth is the most instructive, because it researched adherence 
rates for 6 different regimens. 70 The best adherence was with a simple two-drug 
unchanging 6 month regimen. This was the only study to specifically state adherence 
rates (% doses taken/prescribed), but a weakness was that unlike other studies, 
therapeutic outcomes of each therapy group were not specified separately. As 
mentioned before, both adherence rate and therapeutic outcomes are ideally recorded. 
Biddulph's study shows the benefits of short-course chemotherapy (SCC) in children. 6 
Before SCC was introduced, over 40% of all paediatric beds were taken up by 
tuberculosis cases, and there was a 25% completion rate for the 18 month regimen. 
With the introduction of SCC, the completion rate increased to "approximately 75%". Additional benefits were reduced failure, relapse and toxicity rates. Weaknesses of his 
study were that there was no control group, and that the completion rates were not 
accurately measured. 
The Nigerian study of Oviawe and Ojemudia investigated those who failed to complete 
their treatment, defined as non-attenders. 59 The mean duration of therapy prior to default was 20 weeks. The significant findings are shown in Table C: the non-attenders 
had a shorter initial hospitalisation, had more disruptive events in the family, and the level of maternal education was lower. This was not short-course chemotherapy, however. 
Dick found that the rate of adherents(% adherent enrollees) was higher in those using 
a "community" supervision option, as opposed to supervision at the clinic. 26 This was 
short course chemotherapy, but the regimen used was not specified. 
The study by Beyers et al showed that 88% of the children completed their treatment 
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by 6 months. 5 They used 80% as the categorical cut-off for adherence. Weaknesses 
were that therapy was not specified and that numbers were too small for statistical 
analysis. It was noted that those from urban squatter areas were possibly less 
adherent. 
These studies have shed little extra light on the subject of adherence to tuberculosis 
therapy in children, and highlight the fact that little is known about this subject. Key 
points are that long duration of therapy - 12 and 18 months above - led to greater 
nonadherence, that high rates of adherence are possible with regimens of 6 months' 
duration and that maternal education and a stable family were associated with better 
adherence. A study by Seth showed that a simple unchanging daily regimen resulted 
in excellent adherence. 
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3. METHODS 
3.1 Definition of terms: 
Classification of tuberculosis in the children 
Modified WHO criteria for childhood intra-thoracic tuberculosis were used to classify the children as suspect, probable or confirmed cases. 97 Suspect cases were those with 
suspicious chest radiograph and suggestive clinical features (cough, wheeze, failure to thrive). Probable cases were those with suggestive chest radiographs (hilar 
adenopathy with/without parenchymal lesions, a miliary pattern or pleural effusion); or 
suspicious chest radiograph (peri-hilar opacification with/without parenchymal lesions) 
with a positive tuberculin skin test or a positive contact. A Tine test where two or more papules were confluent was considered positive, and equivalent in significance to a Mantoux test of 15mm induration. Confirmed cases had a positive sputum or gastric 
washing culture for M.tubercu/osis. Parenchymal disease was defined as those with initial chest radiographs displaying any of the following: segmental involvement, with 
or without hilar adenopathy; cavities; bronchogenic spread; or miliary disease. 
Adherence 
75% was the cut-off used operationally by the services at the time of the study.26 Adherence was defined as 75% or more of doses taken/prescribed. Adherents were those who achieved 75% or greater adherence over the total treatment period, while 
nonadherents were those who achieved less. Para-adherers, a term coined by this 
study, included those who exhibited any sustained nonadherence. It therefore 
encompasses all the nonadherers, plus those classified as adherents, but who took 
<75% of doses over any block of four weeks. Excellent adherers were those who were 
not para-adherers. Adherence was measured over 24 weeks. 
Crowding index 
A value of >2.5 of this formula: (adults + [children <10 years]/2)/sleeping rooms indicates crowding. 18 The social data collected in this study included all children under 18 (and not under 10), so the formula was modified: (adults + [children <18 years]/2)/bedrooms. This method underestimated the crowding. 
36 
3.2 Study design and methods 
Ethics 
The study was a collaborative venture between the Western Cape Regional Services 
Council (now the Cape Metropolitan Council) and the Departments of Paediatrics and 
Child Health of the Universities of Cape Town and Stellenbosch. The study was 
approved by the respective Ethics and Research Committees of these institutions. 
Design and sample size 
The study was a clinic-based open randomised controlled clinical trial. The size of the 
cohort (an intended 103 in each group for an alpha error of 5% and a beta error of 
20%) was constructed on the basis of the effectiveness of therapy - given an 
achievable 98% cure rate for the control group, a cure rate of less than 88.3% would 
be significantly different in the intervention group. Using the same sample size and a 
65% adherent rate for the controls (as informed by the literature), a rate of 81.3% or 
above for the experimental group would be statistically significant. Enrolment stopped 
once 222 children were enrolled. 
Setting and study population 
The study took place at the ldas Valley Clinic, a regional referral centre for the 
diagnosis and treatment of tuberculosis in the greater Stellenbosch district. All children 
diagnosed as pulmonary tuberculosis in the district during the period June 1991 to June 
1995 were admissable. 
Inclusion and exclusion criteria 
Inclusion criteria were: children <14 years with intra-thoracic tuberculosis; home 
address in the areas served by the following clinics: Delft, Dennemere, Hillcrest, 
Kleinvlei, Lwandle, Macassar, Malibu, Mfuleni, Northpine, Russell's Rest and 
Scottsdene; accompanied by parent or legal guardian to the ldas Valley Clinic. 
Exclusion criteria were: home address in a farming or rural area; no consent; previous 
tuberculosis; more than 30 days' hospital treatment; extra-thoracic tuberculosis. 
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Data measurement 
At enrolment, a detailed clinical assessment was performed. This included a history of BCG immunisation, duration of illness, symptoms, details of tuberculosis contact and 
whether the contact was smear or culture positive for M. tuberculosis; socio-demographic details (age, sex, room occupancy, employment of adults in the 
household); a full clinical examination, including weight and height; tuberculin skin test 
and chest radiograph. Weight was measured using a Tanita baby scale for those who 
could only lie or sit, and a balance-arm scale for the rest. Length was measured in 
those under 3 years, and height was measured in those over 3 years. Only one set of 
measurements was done in each case. Nursing staff were trained at the outset in these procedures. All those enrolled were clinically assessed by the author of this dissertation. Sputum or gastric washings for M. tuberculosis culture were not done in 
the clinic, but were often available in those who had been referred by a hospital. Children diagnosed as having tuberculosis were randomised by household unit to 
receive either intermittent therapy ( called Regimen 2 for two times a week) or 
conventional therapy (called Regimen 5 for five times a week) - see Section 3.3: Drug 
administration procedure. Randomisation was by random number tables: an odd 
number would assign the household to Regimen 2 and an even number would indicate Regimen 5. Households rather than patients were used in the randomisation process 
to avoid confusion in a household in the event of more than one child from a particular household being enrolled. A standard questionnaire was completed, along with the 
consent form (Appendices 1 and 2). Consent was taken after randomisation, for the purposes of informed choice or consent. 
Follow up times were 3, 6, 12 and 18 - 30 months at which visits the children were 
assessed according to 4 criteria of change: history from the parent, clinical condition, 
weight and chest radiograph, and scored according to the schedule set out below: 
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SCORE 
Criterion 
-1 0 +1 +2 Parent's Assessment Worse Not better Better Much Better Clinical Assessment Worse Same Better Much Better Weight Gain Lost weight Same Gained weight Significant gain 
(ipsi-centile) (Crossing centiles) Chest Radiograph Worse Same Some clearing Definite clearing The score range for each criterion was -1 to +2, giving a possible combined score range at each visit of-4 to +8. 
The data on adherence for each patient were recorded per dose by the community clinic nurse on the treatment sheets, by initialling a sequentially dated and numbered block for each dose given. The sheets (Appendices 3 and 4} were returned to the ldas Valley Clinic on completion of treatment for analysis. Exact dates for the adherence and default patterns were then recorded using a calendar by the following method: the first 24 weeks were divided into consecutive 4-week blocks. The number of doses taken during each block were counted. Should the adherence have been <75% for any block, it was noted as nonadherence. Blocks of four weeks were used in order to compare twice and five times weekly dosing - over any shorter period the adherence rates of the two regimens would not have been comparable, because the denominators are different. The first episode of non-adherence was then inspected, and the date of the first missed dose was entered as the date on which the default pattern began. 
Standardisation and data quality 
The author of this thesis collated all the initial and outcome data. Paediatricians on the research panel visited the ldas Valley Clinic twice a month to perform the diagnostic and radiological review for enrollees and follow-ups. They were blinded as regards the treatment regimen. The research technologist collated the adherence sheets, and classified the adherence as per the method above. She also entered all data into the database programme. As the study progressed, the coding list was revised and appears as Appendix 5. A complete audit of all data fields was done in November 1993, and at the end of the study. There was no independent checking of the database, nor sub-sample verification. 
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Analysis of the data: 
The data were analysed using Epi Info database programme. 22 Non-parametric techniques were used to compare medians of groups (Kruskal-Wallis). Continuous variables were expressed as median (quartile 1 - quartile 3). The chi squared test was used for categorical variables and contingency tables. AP value of <0.05 was taken as significant. A small computer programme was written to derive data from the database (Appendix 6). 
3.3 Drug administration procedure 
All treatment was supervised, either professionally or by the parent. The parents and their children were required to present themselves at least weekly at the community clinic to collect the children's therapy, whatever the regimen. Those on intermittent therapy (Regimen 2) received isoniazid, rifampicin and pyrazinamide for 2 months, followed by isoniazid and rifampicin for 4 months (2H2R2Zi4H2R2). The doses were isoniazid 15 mg/kg/dose, rifampicin 15 mg/kg/dose and pyrazinamide 55 mg/kg/dose. Those on conventional therapy (Regimen 5) received 3 drugs Monday to Friday for 6 months (6H5R ?- J at the following doses: isoniazid 10 mg/kg/dose, rifampicin 1 O mg/kg/dose and pyrazinamide 25 mg/kg/dose. lsoniazid and pyrazinamide were in tablet form, rifampicin was either a syrup or for the older child in capsule or tablet form. For both regimens, the dosages were rounded off to the nearest tablet. The dosages available were: isoniazid: 50mg, 75 mg, 100mg, 200mg and so on. Pyrazinamide was available in 500mg tablets, which could be quartered to give a multiple of 125 mg. Rifampicin was titratable to the nearest 20 mg up to 300mg in syrup form, and thereafter by 150 mg as a capsule or a tablet. 
There was no direct cost to the patient for the medicines, the investigations nor for the transport to and from the referral clinic. No embargoes were placed on diet or exercise. Those on twice weekly therapy received a full 6 months'(= 26 weeks) therapy, whereas those on five times weekly therapy got the conventional 51/ 2 months' (= 24 weeks) therapy of the service at the time of the study. 
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4.RESULTS 
4.1 ENROLLEES 
There were 318 eligible for enrolment. 4 children were refused enrolment by their parents. The patient flow or trial profile is described in Table 1. 
Eligibles 
less Refusals 
TABLE 1: Trial profile 
Total 
318 
4 
Randomised 314 
less Tuberculin and radiograph negative 24 
less Tuberculin positive, radiograph negative 68 
Enrollees 
less Pre-treatment exclusions 
Inception cohort 
less Exclusions from analysis 
Cohort analysed, by intention to treat 
222 
.9 
213 
z 
206 
Regimen 2 Regimens 
153 
12 
43 
98 
~ 
95 
Q 
89 
161 
12 
25 
124 
Q 
118 
1 
117 
The data were analysed as initial data, outcome data and adherence data. 
4.2 INITIAL DATA 
Altogether 222 children were enrolled, 98 on Regimen 2 and 124 on Regimen 5. Recorded consent for their children's participation was obtained from the parents or guardians in all except 14 (6.3%) cases. All parents/guardians gave verbal consent. 
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Exclusions: 
There were 9 exclusions for pre-treatment reasons: 
Table 1a: Pre-treatment exclusions 
Total Regimen 2 Regimens Exclusions 9 3 6 Female/ Male 5/4 2/ 1 3/ 3 Reasons for exclusion: 
Prior tuberculosis treatment 1 2 Diagnosis change 1 2 Treatment incorrect 1 1 Incomplete initial data 0 1 
There were no statistically significant differences between these small groups. 
This left 213 children on the study, whose baseline data are given overleaf. All the data 
were analysed first for any differences between the two treatment regimens and then for any differences between the two groups identified retrospectively by the treatment records as adherent and nonadherent. 
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Number 
Female/ Male 
Age in months: 
Weight in kg 
Weight for age median % 
Height in cm (N = 187)* 
Height for age median % 
Crowding index: (N = 205)* 
Table 2: Baseline data 
Total Regimen 2 Regimen 5 P value 
213 95 118 
107/ 106 46/ 49 61/ 57 0.68 
25.9 24.9 27.9 0.58 
(15.4-41.7) (13.4-40.5) (16.9-43.2) 
12.0 11.5 12.1 0.23 
(9.4-14.0) (9.0-14.0) (10.0-14.4) 
93.1 89.6 96.6 0.015 
(84.0-103.1) (82.4-100. 7) (86.1-104.0) 
85.0 83.6 86.0 0.37 
(75.0-94.7) (74.0-95.0) (76.0-94.5) 
95.3 95.0 96.2 0.09 
(92.9-99.9) (92.6-99.3) (93.2-100.8) 
3.3 3.3 3.3 0.66 
(2.3 - 4.3) (2.2 - 4.1) (2.3 - 4.5) 
*Please note that heights of 26 children (12.2%) were missing, as were the full data on crowding for 8 children (3.8%). Figures in brackets are the interquartile ranges. 
Because of the use of the inception cohort/ intention-to-treat method, 102 there should 
have been no further exclusions. A further 7 children, however, were excluded because 
their adherence monitoring sheets could not be analysed properly, having been mislaid 
in 6 cases. The seventh sheet was indecipherable, the child having received both forms 
of therapy. Of the 7 children, 6 were on Regimen 2, the twice weekly regimen. This left 
206 children in the study. Using the same criteria as above, the P values are very 
similar, as seen in Table 2a overleaf. 
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Table 2a: Baseline data - P values for N = 213 and N = 206 
(N=213)* 
(N = 206)* 
Sex Age 
0.68 0.58 
0.69 0.62 
Weight Weight/Age Height HeiqhUAge 
0.23 0.015 0.37 0.09 
0.32 0 030 0.24 0.11 
*The numbers for Height, Height/Age and Crowding are fewer, as noted above 
HISTORIES: 
Crowding 
0.66 
0.90 
The histories did not differ between the 2 groups, and specifically not in the stated history of weight loss. Tuberculosis contacts: There were 142 (69%) children with a documented contact, with no difference between the treatment groups. These contacts 
were thoroughly reviewed in terms of their bacteriology, but again no difference could be found between the groups. Prior generation contacts were the commonest. 
EXAMINATION: 
The only difference in the examination is noted above - those on Regimen 2 had a 
significantly lower weight for age. As Regimen 2 was not the control regimen, this difference would not complicate the interpretation of the results. 
DIAGNOSTIC CLASSIFICATION: 
There were no differences between the groups in terms of diagnostic catagories. 
Confirmed cases 
Probable cases 
Suspect cases 
Table 3: Diagnostic categories 
Regimen 2 
4 
82 
~ 
89 
Regimen 5 
4 
111 
2 
117 
P value 
0.68 
There were 67 subjects with parenchymal disease, 27 (30%) on Regimen 2 and 40 (34%) on Regimen 5, with no statistical difference between the groups (P=0.66). One 
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child with a miliary-like picture on the chest radiograph was treated as an out-patient 
with fully intermittent therapy from the start. The child was not ill enough to warrant 
hospitalisation, and was carefully watched clinically. 
4.3 TREATMENT OUTCOME DATA 
The first measure of adherence is biological or therapeutic outcome. There was no 
difference in the outcome between the 2 groups: 
No. discontinued therapy 
at scheduled time 
3 months 
Number scored 
Outcome score median 
6 months 
Number scored 
Outcome score median 
Median weight gain 
by 6 months in kg* 
Table 4: Outcomes v Regimen 
Total Regimen 2 Regimen 5 P value 
199 85 (96%) 
70 (79%) 
5 (4-6) 
68 (76%) 
6 (5-7) 
1.5 
(1.0-2.1) 
114 (97%) 0.59 
89 (76%) 
5 (4-7) 
94 (80%) 
6 (5-7) 
1.75 
(1.2-2.3) 
0.40 
0.24 
0.37 
0.90 
0.21 
"\/Veigh1s for 167 (81 .1%) children were collected at 6 months, 69 (77.5%) on Regimen 2 and 98 (83.7%) on Regimen 
5. Ranges in brackets are the interquartile ranges. 
There were no differences in the scores between the groups at 3 or 6 months, nor in 
the weight gain. 
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4.4 ADHERENCE DATA 
The second measure of adherence used in this study was the percentage of doses 
taken/ doses prescribed: 
Table 5: Adherence by Treatment Group 
Total Regimen? Regimen 5 P value 
Number 206 89 117 
Adherence% 91.5 93 91 029 
(76-97) (75-100) (77-97) 
Nonadherers 
Number(%) 46 (22.3%) 19 (21.3%) 27 (23.1%) 0.90 
Median days to default 50.5 72 42 0.08 
(34-84) (44-93) (33-69) 
Para-adherers 
Number(%) 97(47.1%) 40 (44.9%) 57 (48.7%) 069 
Median days to default 74 88.5 57 0.07 
(39-110) (50-126) (35-105) 
Ranges in brackets are the interquartile ranges 
For clarity, 1he nonadherers are 1hose whose total adherence % was <75%; the para-adherers include all nonadherers, plus those classified as adherents, but who took <75% of doses over any block of four weeks. 
It is clear that a high adherence rate was achieved, and that there was no difference 
between the two treatment groups. It is also clear that some nonadherent behaviour 
was exhibited by nearly half the subjects. Time to default was longer for the twice 
weekly group, but the difference is not significant. The nonadherent group tended to 
default earlier than the para-adherers. 
Thus the treatment results and the adherence rates achieved for both groups show no 
statistically significant difference 
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The adherence over time for all subjects in the study is shown in the following bar 
graph, in terms of both adherence and adherent rates: 
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Figure 1: ADHERENCE v TIME 
Month 2 Month 3 Month 4 Month 5 
The "months" are actually consecutive 4 week periods 
~ Mean percentage adherence 
(% doses taken/prescribed) 
D Proportion of children adherent 
The falloff in adherence over time is clearly demonstrated. 
Month 6 
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In order to determine any differences between those adherent and nonadherent, the 
subjects were grouped using 75% of total doses taken/prescribed as a cutoff. The 
adherence over the first month is compared to adherence over the rest of the therapy 
period using the median ( 100%) as the cutoff. 
Number 
Regimen 2 
Regimen 5 
First month's adherence 
100% 
< 100% 
Table 6: Adherers v Nonadherers 
Total 
206 
89 
117 
Adherent Nonadherent 
160 (78%) 46 (22%) 
70(79%) 19(21%) 
90 (77%) 27 (23%) 
140(68%) 119(85%) 21 (15%) 
66 (32%) 41 (62%) 25 (38%) 
Crowding index median 3.3 3.0 
(2.2-4.0) 
4.3 
(3.0-5.0) (2.3-4.3) 
Median age 26.1 30.1 20.7 
(15.4-41.7) (16.6-46.0) (9.5-32.1) 
Outcome score median 
at 6 months (n=162) 6 (5-7) 6 (5-7) 6 (5-6) 
Ranges in brackets are the interquartile ranges 
P value 
0.90 
0.000 2 
0.002 
0.001 
0.10 
It is clear that crowding, and adherence over the first month are powerfully related to 
nonadherence over the entire period of treatment. Younger age seems to be a factor 
which mitigates against good adherence. There was no difference between the disease 
outcome score for the two groups 
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The results for crowding and adherence over the first month are even more marked if 
one takes the nonadherent group as those defaulting at any stage of therapy: 
Table 7: Exce!!ent adherers v Para-adherers 
Number 
Regimen 2 
First month's adherence 
100% 
< 100% 
rr/"\\Alrlinn inrlov modi!:ln '"'' -·1'-11 ·~ II,......, __ 111- 1-1 
l\,1orli::in !:ll"IO 
11'1--1-1 I-~-
()1 1trnmo c:rnro rnorli::in '-'"""""'_-...,I I I- __ .....,, '-' 111'"'""''....._I I 
at 6 months (n=162) 
206 
89 
117 
140 
66 
3.3 
(? ~-ll. ~, 
,--- ·--, 
26.1 
11 i:; .d-ll.1 7\ \. -.. " . ' I 
6 (5-7) 
Ranges in brackets are the interquartile ranges. 
Excellent 
adherers adherents 
1no 1c:;~01n, o7 1,1701,,\ 1-- \--,v/ -• \ ,, ,v/ 
49(55%) 40(45%) 
RQ f~,101,, \ 51 (36%) --,-•,vj 
?n nno1n \ L1h (7()01,, \ 
-- ,~- ·-, ·~ \' -·-, 
3.0 4.0 
(1 Q_~ Q\ n ru; m \. ·- -·-, ,--- -·-1 
30.2 25.1 
(16.3-45.8) (13.3-36.3) 
6 (5-7) 6 (5-7) 
P va!ue 
0.59 
0.000 02 
0.000 2 
0.14 
0.28 
For clarity, the para-adherers include all nonadherers, plus those classified as adherents, but who took <75% of doses 
over any block of four weeks. Excellent adherers are the rest 
The value of P is enhanced by comparing any period of default during the treatment 
period against the crowding and adherence over the first month. The association 
remains if the adherence over the first month is compared against the subsequent 
adherence. So the propensity to nonadherence is strongly associated with these 
variables in this study. The association between nonadherence and young age has 
become nonsignificant when the definition of nonadherence was broadened. 
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Table 8: Adherence and Treatment Clinic 
Clinic Non adherent Para-adherent Adherent P value 
Delft 0 0 3 
Dennemere 0 2 10 
Hillcrest 0 0 2 
Kleinvlei 6 12 26 
Lwandle 17 8 11 
Macassar 5 4 23 
Malibu 0 1 1 
Mfuleni 5 7 9 
Northpine 0 0 3 
Russells Rest 0 5 10 
Scottsdene 13 12 11 
TOTALS 46 51 109 0.0002 
0.0008 
It is clear that adherence rates differed markedly between clinics. Those clinics with 
more nonadherence are also those intuitively in the poorer suburbs, but there are no 
easy objective means of testing this. 
Negative findings 
There was no difference between the treatment groups in the falloff in adherence over 
time. There was no difference in the duration of illness prior to finding help between the 
two therapy groups, between the adherence groups, nor if tested against disease 
severity. There were no notable side-effects of treatment, apart from initial vomiting in 
children on twice weekly pyrazinamide at 62.5 mg/dose. When the dose range was 
lowered to 55 mg/dose, this problem did not recur. Except for persistent vomiting (there 
were no such cases), adverse drug events were not systematically recorded. One 
subject (#63), on Regimen 5, developed a mild rash of short duration. 
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5. DISCUSSION 
This was a clinic-based open randomised controlled clinical trial to assess the 
effectiveness of and adherence to twice weekly therapy for childhood tuberculosis. The 
evaluation of this study according to the scoring system developed by Haynes, Taylor 
and Sackett40 for studies on adherence, "Methodologic standards for compliance 
research reports", follows. There are six categories which are separately scored with 
.· the maximum score in brackets: 
Study design (4 +1 •) 
Selection & specification of study sample (3 +1) 
Specification of the illness or condition (3 + 1) 
Compliance measures (4 +1) 
Definition of the therapeutic regimen (2 + 1) 
Definition of compliance (2) 
TOTAL (18 +5) 
·son uses are scored if certain specifications are met. 
This study 
Randomised trial 
Referral centre 
Replicable criteria 
Pill count/Rx refill 
Complete description 
Replicable 
Score 
4 +1 
2 +1 
3 
2 +1 
2 
2 
15 +3 
It is clear that by this estimation, this study rates highly in terms of "adequacy of 
methods" that produced the results. 
5.1 Limitations 
5.1.1 Desian: 
Randomisation controlled for confounding. The possible bias that blinding could have 
had on the study needs to be considered. It should be noted that this was an 
effectiveness trial, therefore patient blinding was not a consideration, as this would 
have negated the aim of testing twice weekly therapy under field conditions. As regards 
researcher blinding to the study regimens, the clinician who saw the patients was not 
blinded, but the review paediatricians who did the outcome measure scoring were. As 
the main outcome measure for the effectiveness of therapy was based on the scoring 
done by the blinded pane!, it is unlikely that this aspect created a bias. Lastly, it is 
noted that placebo control was considered unethical. 
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5.1.2 Subject selection: 
The subjects were selected from clinics in urban and peri-urban areas only, not from 
the farming areas which are served by mobile clinics. The farming areas were omitted 
because they could not be monitored on a daily basis. An urban or peri-urban bias thus 
occurred. Additionally, for the purposes of informed consent, the parent had to be 
present at the initial interview. In most instances, this was conducted at the ldas Valley 
Clinic in Stellenbosch, some 20 - 30 km from each of the clinics mentioned above. The 
parent was thus bussed in with the child. Those unwilling to accompany their children 
were then automatically excluded. Consent was taken after the parent was told " ... 
should you decide to enrol your child onto the study, s/he will be given 2/5 times a week 
treatment ... " It is unlikely that this process biassed entry onto the study, as there were 
4 refusals only. Although this study was done in a regional referral centre where all 
tuberculosis patients in the area of jurisdiction of the clinic were bussed in for initiation 
of out-patient therapy, the patients were by no means consecutive admissions. This 
was mainly because among the different doctors doing the tuberculosis sessions, only 
the project leader was considered expert enough in childhood tuberculosis to enrol 
patients onto the study. The logistic time constraints of enrolling a patient also curbed 
the number entered onto the study. 
5.1.3 Data not collected: 
The enrolment refusals should have been systematically recorded with regard to the 
stage at which they refused and their intended treatment group. They would also 
constitute part of the inception cohort in its most liberal definition of intention to treat. 
For the purposes of an adherence study, more data on the families of the subjects 
should have been collected, like parental income, parental ages, education status, 
employment/professional status, marital/family status, and possibly race. Other data of 
importance would have been the distance and/or the time to the clinic from home, which 
could have influenced the adherence. The clinics are by and large situated in the 
communities they serve, so the effect of this variable is not expected to be great. 
Data on who supervised each dose - parent or professional could have been collected, 
and could have been a source of bias. It could be argued that parental supervision is 
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a form of self-supervision. Both methods of supervision, professional or parent, fall 
however into the same category of Haynes, Taylor and Sackett, being "Objective 
indirect measures".40 Because the adherence study was tagged on, these data were 
largely irrecoverable, inter alia because of the time elapsed. 
Co-morbidity should have been described. This would have determined whether 
adherence was associated with other illnesses. Compliance estimation would have 
improved had a better method been used, eg. random urine testing for isoniazid. No co-
interventions were noted. A record of all side effects and unusual events that occurred 
during therapy should have been kept, as well as action taken by the services. The time 
spent at the initial interview was not recorded: one group could have been more 
intensively counselled. 
5.1.4 Data not analysed: 
The address of the patient could have been analysed for distance to the clinic, and the 
effect on adherence. The effect of no consent was not analysed for adherence. 
5.1.5 Categorisation: 
Data were categorised for ease of data handling. Some of the significant associations 
could not have been produced using the Epi Info programme had the data not been 
categorised, eg. age v nonadherence and crowding v doses taken. 
Despite the above limitations, the high score obtained on the Haynes Taylor and 
Sackett assessment method, and the fact that the biases and limitations have little 
impact on the categorisation of the subjects into different groups - treatment regimen 
and adherence - on which the results are based, allows one to conclude that the 
methods are acceptable. One can thus continue to discuss the results. 
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5.2 Discussion of Results 
5.2.1 RESULTS BY REGIMEN 
Randomisation: 
Almost half (48.7%), of the 314 were randomised to Regimen 2. The final cohort 
analysed, however, contained only 43.2% on Regimen 2 mainly because there were 
many more on Regimen 2 who were tuberculin positive yet radiograph negative than 
on Regimen 5. 
Exclusions: 
The nine subjects (4%) of Table 1a were excluded for pre-treatment reasons. This is 
a common phenomenon in clinical trials, and there was no obvious bias here. Seven 
of the treatment sheets were indecipherable or mislaid. Six of these were from the twice 
weekly group, but the numbers were small and the baseline P values for the original 
group of 213 and the subsequent.206 assessable were no different when the two 
therapy groups were compared, so this was not a significant source of bias. 
Baseline data: (Table 2 and Table 2a) 
The weight for age median was statistically lower for the test group. This was a random 
variation in data, and had no further effect on the study, as is seen by the weight gain 
at 6 months. The missing data were irretrievable, as both height and crowding data 
change with time. The results showed clearly that the other data at inception were no 
different between the groups. 
Diagnostic classification: 
Table 3 shows that most children were classified as WHO probable cases. This is 
expected in a clinic based study where facilities for gastric aspiration are not available 
or feasible. When gastric aspirates have been evaluated in clinic based studies, little 
more than 10% of cultures have been positive for M tuberculosis. 4 
Outcomes: (Table 4) 
Almost 97% of the subjects had their therapy discontinued at the scheduled time. This 
is excellent for a study testing adherence and two different regimens as further doses 
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then do not contaminate the results. There were no differences between the therapy 
groups in the clinical outcomes measured at 3 or 6 months. 
Adherence rates: 
High overall adherence rates were achieved for both regimens. These are somewhat 
higher than found in the studies mentioned in the literature review. The differences are 
explainable in that it is the adherence rate reported here, which can be higher than the 
total adherer rate - which in this case is 78% (yet the median adherence is 91.5%). It 
may also reflect the Hawthorne effect, namely the positive effect on adherence merely 
because the subjects knew that they were being studied. The falloff in adherence over 
time needs no elaboration here, being well documented in many adult tuberculosis 
studies. 10 It is notable that the falloff phenomenon is reflected in this childhood study, 
and is probably a function of care-giver (adult) adherence. The nonadherer rate is 
essentially the same as that of other studies, and the para-adherer rate of nearly half 
confirms very well the views expressed by Rouillon54 and Dic~6 that it is normal to 
default. It is also clear that the adherence rates for the two regimens are no different. 
The time prior to default in both the non adherers and para-adherers is longer for the 
twice weekly regimen, but as seen, is not statistically significant. 
5.2.2 RESULTS BY ADHERENCE (Tables 6 and 7) 
77. 7% of the subjects were adherent, having taken at least 75% of the doses 
prescribed. The statistically significant findings were that the first months' adherence 
was predictive of subsequent adherence, that crowding was statistically higher in the 
nonadherent group, and that those nonadherent had a younger age. Broadening the 
definition of nonadherence consolidated only the first two of these findings. 
The outcome scores at 6 months showed no difference by adherence status. This 
finding is not unexpected, as the natural history of primary pulmonary tuberculosis is 
spontaneous resolution, especially if the patient is well enough to get clinic treatment, 
as was the case here. As noted in the literature review, the level of adherence needed 
for safe resolution of primary pulmonary tuberculosis is unknown, but it is likely that 4 
months' therapy is sufficient, based on work in adults with smear-negative 
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tuberculosis. 30·45 It may well be that this unknown level was achieved by those 
nonadherent in this study. It is noted that the latest regimens for childhood TB in South 
. 
Africa recommend 4 months' treatment for pulmonary tuberculosis.25 
Young age and adherence: 
Table 6 shows a significant association between younger age and nonadherence, but 
this is not reflected in Table 7, where the definition of nonadherence is broadened. One 
feels intuitively that younger age would result in greater adherence - the care-givers 
being more concerned - yet this finding shows the opposite. It could be an effect of 
being more difficult for the care-giver to get the younger child to the clinic. More likely 
it could be a true random finding, because the association disappears when the 
definition of nonadherence is broadened. 
First month's adherence and subsequent adherence: 
This finding was expected, as was highlighted by Sumartojo. 79 This phenomenon could 
be used by the clinic staff to predict and prevent subsequent nonadherence. 
Crowding and adherence: 
Crowding is probably a proxy for socio-economic status. Crowding was negatively 
associated with adherence. This was a new finding. It is exciting because, if proven 
elsewhere also, could be an easily measured demographic characteristic which can be 
used to predict nonadherence, and so spark preventive management. Nurses usually 
take down family details in order to trace contacts, so this would entail little extra work. 
There were insufficient factors studied to more fully explore the relationship between 
crowding and nonadherence, like parental education status. An unmeasured or 
unknown confounder is possible here. Nonetheless, an association is present, and 
could be used in practice. 
Address and adherence: 
The busier and poorer area clinics were associated with poorer adherence. In the 
absence of research-measured comprehensive data on the clinics' activities, it is 
difficult to draw accurate conclusions from this data. 
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6. CONCLUSION 
There were no differences in the disease outcome criteria. There was no difference in 
the adherence rates between the regimens. The null hypotheses thus cannot be 
rejected, as there were no differences in the clinical outcomes nor in the adherence 
rates between the two forms of treatment. A higher crowding index was predictive of 
poor adherence. Adherence in the first 4 weeks was predictive of adherence over the 
rest of the therapy period. 
The finding that adherence in the first month was predictive of adherence over the 
entire treatment period is not new, but has once again been strongly validated. Another 
and maybe more important finding was that one could predict nonadherence using an 
easily measured and computed crowding index. Although this finding was made in a 
childhood study, it is new to the literature, and is contrary to assertions that 
demographic data are "poor predictors of adherence" (Sumartojo79). The fact that 
crowding was predictive of nonadherence over the entire period of treatment and for 
any 4 week period of nonadherence, and that the second group was double the first, 
shows that this finding is robust. 
This research cannot answer questions like why clients (or their parents) fail to adhere, 
and why do they not come earlier or at all for therapy. These considerations are 
highlighted by Sumartojo79, and by Dick.26 Quantitative research such as this will not 
address these larger questions in adherence, but can identify areas for improvement 
and be used to monitor programmes' success or failure. Although the treatment of 
children is not important in the control of tuberculosis (this lies mainly in the proper 
treatment of infectious adult cases and in socio-economic upliftment of our society) 
large numbers of children do fall ill with tuberculosis. This is related to the extent of the 
epidemic and the high annual risk of infection. These children place a burden on the 
tuberculosis control programme and the health services in general. Furthermore, a 
primary infection successfully survived is thought to generate a 60 - 80% protection 
against subsequent pulmonary tuberculosis from re-infection. 80 
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7. RECOMMENDATIONS 
The findings show that in terms of treatment for childhood tuberculosis, the outcomes 
and adherence achieved with either treatment modality are identical. This is good news 
for the services, which should be looking to converting all therapy to intermittent, based 
on studies such as these. It is possible to supervise all therapy if it were intermittent, 
but it is not possible to supervise all therapy in the current setup of daily treatments. 
This point was made as far back as 1967,31 and reiterated in 1996.96 
It is recommended from this study that routine clinic based tuberculosis therapy for 
children be changed to fully twice weekly - demonstrated by this study to be no different 
in terms of outcome and adherence - provided that the long term follow-up of the 
intermittent therapy group shows no significant relapse rate. Although a rural setting 
was not studied, there is no reason to believe that this form of treatment delivery would 
not be generalisable to a rural setting. This would reduce the workload on the services, 
as well as being cheaper, by 40 - 60%. 10· 39 
There may be concern about the possible emergence of drug-resistance with 
intermittent treatment. With regard to childhood tuberculosis, the disease is 
paucibacillary, and it is only where one has cavitation with of the order of 109 organisms 
that drug-resistance is a threat. With regard to adult tuberculosis, the chance of 
resistance is greater because of the greater loads of bacilli present. There is theoretical 
evidence, however, to suggest that pulsed intermittent dosing is more likely to eliminate 
the emergence of secondary resistance, by targetting the bacilli in the growth phase.57 
Also, the logistical possibility of all doses being supervised is greater with the reduced 
workloads in intermittent therapy, thus reducing the emergence of secondary 
resistance, which is the commonest form of drug resistance. 
In terms of the proactive management of adherence in childhood tuberculosis, the 
recommendations from this study are that: 
1. crowding be measured at the start of therapy to identify possible nonadherers, and 
2. adherence over the first month be measured. 
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Should either measurement be suboptimal as regards predicting nonadherence, action 
should be instituted to ensure or enhance adherence. The clinic staff would in these 
ways be able to manage nonadherence preventively, having identified those at risk, 
instead of managing it once it occurred. This process should be monitored in practice 
to ensure that the predictability of nonadherence was not merely a research 
phenomenon. 
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Appendix 1: Standard Questionnaire 
STELLENBOSCH RSC TB STUDY 
DATE 
DATA COLLECTION FORM RING EITHER THEY or N 
Name .•....••••••••• <•u~n-..n•>••••••••••••••• Date of Birth .. / .. / .. Clinic number •••••••••.••. //Hospital...... No .•..•.•••.•.•.•.••. 
Address .....••••••••••••••...•.•............•••.....••••.•••.•.••. 
History: Duration of illness •..•.• weeks 
Cough Y/N Fever Y/N 
Loss of appetite Y/N Loss of weight Y/N 
Listlessness Y/N Breathless YIN 
Recently in Hospital?/Other (list) •.... 
Wheeze Y/N 
Sweats Y/N 
Contact: Spec:ify i..iho ••••••••••.••••.•••..••••••••..••••.••••••••. 
Contact microscopy+ Y/N 
Contact culture positive Y/N 
Contact is a retreatment case YIN 
Contact= good compliance ()75%) Y/N 
Contact= defaulter ()2 months off Rx) Y/N 
BCG: Date given .•• ! ... ! .. . 
Social: Number of adults .. . 
Sleeping rooms per house 
Examination: Weight ....•... kgs; 
Sc2s present Y /N 
Number of children ... 
Number of adults employed 
%EW •••••••• 
Height/length ......... ems; 1. EH •.•••• 
Wt for Ht Green/ yellow/ red/ brown 
Lymphadenopathy Y/N 
E. N. • • Y /N 
Site and size ................. . 
P.C .. Y/N Abd glands Y/N 
Hepar Y/N ~ size .... cm Spleen Y/N , size .... cm 
Resp Distress Y/N Rate ..... acc.muscles/ grunts/ cyan 
Dt her . . . . . . . . . . . . . . . . . 
Investigations: 
TST - Tine grade ..... 
CXF: - NAD 
M2.ntoc.t:: . . . . . mm 
hilar adenopathy only Y/N - segmental lesion only YIN 
- both cf the above Y/N - pleural effusion Y/N 
- cavitatcry disease Y/N - miliary Y/N 
- brohchogenic Y/N - merely suspicious Y/N (Sputum investigation Y/N: microscopy+/ - ; culture+/ -
Diagnostic category: 
Intrapulmonary -TB •. Y/N 
Extrapulmonary -TB •.. YIN 
Case Definite Y/N 
Tuberculin reactor YIN 
Contact only YIN 
Spe::ify .................... . 
Probable Y/N Suspec~ Y/N 
Treatment allocation: No. in the stLtdy .................... . 
Appendix 2: Consent form 
WESJ<AAF·SE STREEKSDIENSTERAAD 
Toestemming tot insluiting in 'n navorsingsprojek 
P,fv.,i.:::,::,;:;.:,lE:·ndc.· T .B., PFihE·.ndc::.·linr,.; Stu,j_ie ( ''die Stu.die''): Goedgekeur d2ur die ~tlp~P Komitees en Liggame van 
i ..i..l ::·:~· .. ::. i :: ·:'="i. .~:,. ;,) ·::. t::, :::~ t: ·:·- E:-:- E· 1< c! .i er·: :~. ·1: E' ·i- E'. -::\ c! (3 f~: ·:::. c:i T'! d !-: E:· id-::~ cf is.• n s-:. t e , F~ o C) i k 1- tJ is. 
< v,..,n > 
t {-:-: D n t. ·-/ -3. T: t~! .. 
standaard/2 dae per week* behandeling 
noodsaaklik dat u kind die volle duur 
v2n die behandeling vol~ooi. 
!:::,,, Dr· .J .. i'1,. +:,:,:; !,-•).:,1-t:~:=.·r·· t-,i.,:1.u.cJ,:c'! verklc:1.::,.r hi1:.,·:-m,::?e d.:c1t ek diE? 
-~.:·0.r·d., de_;;=~·~-~ r-i=-tkci··~- er·: inc.1j-:.:intlikt? Qf?\/c,lg:z::· \.-1.sn die Stu.die 
- - • -- --· -· -- - -- -- -- .. J ··-L_! If U •::.:.' I LI t:: ! I L.!!;.~·::tLJ !;;:.' DUL::Fi / ')!J[lf.:; * 
toestemming te gee, verduidelik het. 
I/ • < d•,i\t:.l..,n, > 
E0 die ondergeteke~de . ( na.;~m •n V.o!i."\n) 
in my hoedanigheid as O~ER/VOOG* oee niermee toestemming 
insluiting van my kind in die Studie, die i=: p :.:; ,=:; ·,·- 1-i h ,:::. .; .-i ~-·-.,! .·J .. ::·r. ·,- \/ -:":i. n Cl E~ Lt:- I) i- ,J :I i~-~ • t e l1J .2-. t (2 i- i'•J Et u. d e a an :Tl\/ 
ve~duidelik is en ek sertifiseer dat: 
L 
':) 
L... • 
r; 
.. :.:" 
L~ " 
Die aard, doel, risiko's en moontlike gevolge 
van die Studie aan my verduidelik is. 
Ek die implikasies van die Studie en die 
risiko's daaraan verbonde aanvaar. 
Die volgende prosedures uitgevoer mag word as 
deel van die Studie: 
i) J::liniese mediese ondersoeke 
ii) toepaslike X-Straal ondersoeke 
iii) Tu.ber-kt.1.l j_t.::n \/E"?J. t,:J,=!tse ( "tj.=1.ppies 11 ) 
iv) e~ige verdere spesiale ondersoeke wat 
klinies aangedui is. 
El:: t_:,,.,~\.--o'::f,J i '3 cm h ie·:-d i e toE·stemmi ng t e gee. 
CHANDTEKENINO VAN OUER/VOOG*> 
Getuies: 1 . 
2. 
* 9.'.i;,·.:3p M::iT NIE V/->tN TOEP/'./SSJ/VG JS NIE 
Weke 
1 
- 2 
3 
4 
C 
·-
.... 
' 
7 
8 
g 
10 
11 
12 
l'.3 
-14 
Appendix 3: Adherence sheet for regimen A 
"'-....: t - '"" 
T.......lL.. lullLtrolevorm: 
~ :S.~.c::<~'."! .. A~.l'~~(i ~":' :s. 
InteIJDit~ Behande1icut ' - ~ : . .... 
Geb. datum: ........ · . ., -. 
Al°iLP:i_;_ 
. ,~ . . Pµi_cp_c_4,.-j,_ . . 0 .... .. . 
. . ~#.q4.0t_ . .......... . 
:3· .. _ ,-. 
Oud: ... J'· ...... _ .. . . 
Toesighouer:. ~!1~1!E:-I~ . . 
Toelatingsgewig: . . .. . 
X-Straal no: . .. . t l .. . 
Behandelingskedule: 
Tine toet s : ~- .. ... . 
Oovolc X-Stral,;: 
. . 
. . . .. ..... ...... .... . .... .... .. 
6/ 12 . ":3 Jz:J;;,· .... . 12/ 12 ......• 3. . . . . 
30/12 .--'>h./.'1.4- ... . 
' _ _.. , . 
, . 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
D~t~~. R:~. ti~g;_~ ;. : :~1ir.:.i?:::: ::: 
Haan. Don. Totaal van Opdragte Weke Haan . Don. Totaal Opd.::agt,:> I Dos i sse van Do-
3\l. i.:12 Feb sisse 
L. . 
1~, 'fl) LL--(kJ Ct.c-) 12. ~ 
ti)l. ,, () 
-~ 
~2.. 2-/-z. 16 I • c'..~4 lL, u~ .. 
il/1- .. ~/2. 
-! 17 :~ ~1r.. • 4., (~ .z. ~-, 
.l.tl2.. i.]Jl.. 1?.. g/8-1():;. "° 18 i:~ ~ .. it.) i)j~ .. l<.,o lil.:.7· -C.. • iCC.:-i 
~g · !:,"/!:, .. 
~{ .. \l"' a_;'4. _ 1:-i . .fu,._. r=.. M,t. 19 40. Ct.--. (i.-. . .......__ 
~ '. 
~ - ~ '1 /3 'l/3 ').lz 20 _ U,O , ... 1 ' ., 
ii./3 !Cf/; l/z 21 ' 0=:, ~G~ ' (.<...,,. a-~ i_,/,,0 • l'l. · 'hh,b 
B/3 2C.J3 
-Z(i. 
.__p I ' 22 ,/. ' 4.....- ~ 
3cJ3 / Yi : ·. ,·.~: % -ICC ·t 23 fJ'..'.? t"i-?, u../ ·1 
/ - ~ -·· .. -~ ¥ - j_r.t-·. Y, ~p.- . 24 '-0 "}.1u\L1 C,J; Cl. I . . 
bl.'f jJ_"-
."J.(). 25 ~sr ~ ' v _ ;, ~, "' [.t:,,J :~ ..._...., ' . - · ) ~ 
-:;;1_:.J.p lvi!; .+,' ).. 26 ,~~ '-b ~ - lf, •, '7 9 - -f:{-;·, 
.. !./.,! f .f 
·~1-;a JI , 9/'o -,et;\ 27 '..1-1 C:/ Ii.(). 1,' -1...., 
- 1:) __ .,.. ,, 
'll.f . 1/1.:, I/ 28 H;;, 9? .. p ' I 
.. , .-;,n 
-
HA.AH: 
Appendix 4: Adherence sheet for regimen B 
L I • · , . . I •• 
., I IC $ D R. ~-· '\ . 
'-J'~,"~\ ~ v\0-.zn..1.\...,_L:-................... (') . .. .. . 
/ 7 ( vi" c ..-l... 'l .. d 
················(?········ 
.. Y. ~ -.?:~ ... ~ ~(~Z; .... 
I · . .'t ,-\ 
STRJ,T,RNBOSCH 
G If -OUD. : ...•. ' •. -:- .-.. • .•• •••. ..•.••.. 
'"'\ 
i, .··· TOESIGHOUXR: .... . : : . ........... . 
VDRL: ...•.......• -•..•.• .. ...... • 
BEHAHDKLIHG: ............................... . .. ... . . . . ............... . 
' ....... ... .... .. .. .. ................................................ . I 
. -~~\~\~,,·;_· l~~ -~ .. -~; ~: .. \~.·.· ·,~i· ~.~~ .-i. :,~~ ·-~ ·_:i·-~.· ..................... . 
• • • • • • • • • • • • • • • • ' • •••••••• " ••• • •••• · - ; •• r')"";' •••• • •• · • •••••••••••••••••••• 
1 ~ _ • I 
~7 ·; BEHAHDELIHG VAHAF: . ·;-.. ·.'?. ':J. I, .....•.... X-STRAAL HR.: ..• . . -:-........ . 
Sputumbottels: 90 dosis 
X-strale 100 dosis 
GEWIG COHPL . 
122 123 124 127 128 
• i----~---:--~-t--~+-----;-~--f---~+-, ~---+-~-+--------+~--+--~___j__~-1. 132 --3 1-::i• 136 I 1.,7 138 I .l.:> ..,.., I ., I .., ' I I 
141 143 I 143 I 144 i 145 I 146 l 147 I 148 I 149 I 15C i i I I I I 
151 152 I 153 I 154 155 I 1ss I 157 i 158 ! 158 1160 l I I I I 161 I 162 I 163 I 164 165 I 166 1 167 ! 158 I 169 i I I I 17C ! I I I I I I 176 i i I ! 180 i I ! 171 172 173 174 175 177 178 179 I I i 
STELLENBOSCH RSC TB STUDY 
CODING LIST 
(stb.rec file) 
1. Name (NAME): 
Child's name and surname 
If"=" next to surname, consent obtained 
Appendix 5: Coding list 
If"#" next to name, slight calcification visible on CXR (mark for 
radioligist study) 
If"@" interesting CXR 
If"$" next to name, child keeps on vomiting on treatment. 
If"%" next to name, Dr. Gie's study (Lymphobronchial TB) 
2. sex (SEX): 
M = male 
F = female 
3. Age (AGE): 
mos= in months 
yrs= in years 
(This calculation is automatically done by DOMEAS by entering birthdate 
and visitdate of child) 
4. Date of birth (BIRTHDATE): 
American date order 
If date of birth is unknown, 01/01/year of birth 
5. Date treatment commenced (VISITDATE): 
American date order 
Date treatment commenced 
6. Initial weight (WEIGHT): 
Initial weight in kilogram - numeric value 
(LBS and ozs are not used in this study - this variables remain empty) 
7. Height for age percentile (HAP): 
Percentage of expected height/length - numberic value 
8. Height for age Z-score (HAZ): 
9. Height for age %median (HAM): 
10. Initial height (HEIGHT): 
Initial height if child >3 years 
1 
11. 
12. 
13. 
14. 
15. 
16. 
Initial length if child <3 years - numeric values in centimeters (FT and IN are not used in this study - this variables remain empty) 
Weight for age percentile (WAP): 
Weight for age z-score (WAZ): 
Weight for age %median (WAM): 
Weight for height percentile (WHP): 
Weight for height z-score (WHZ): 
Weight for height %median (WHM): 
17. Flag (FLAG): 
18. Study no (STELLENBOS): 
2 = intermittent therapy 
5 = standard therapy 
6 = intermittent therapy - excluded from study, but still for follow-u 
7 = standard therapy - excluded from study, but still for follow-up 
8 = intermittent therapy - excluded from study, not for follow-up 
9 = standard therapy - excluded from study, not for follow-up 
19. Clinic number 
(a) (CLINICNUMB): 
First letter of surname - Capital letter (b) (CLINICNUMl): 
Folder number on left hand corner of folder envelope - numeric valu 
20. Hospital (HOSPITAL): 
Big referral hospitals - not local hospitals and day hospitals 
eg. Tygerberg Hospital 
Somerset Hospital 
Red Cross Hospital 
Use abbreviations eg. RXH 
21. No (NO): 
Child's hospital number - numeric value 
22. Address (ADDRESS): 
Name of area - full address not necessary 
Name of area is written on top of folder envelope in pencil 
23. Holiday (HOLIDAY): 
1 = Transkei 
2 = Ciskei 
3 = Montagu 
Parents must report leave to clinic sister for arrangements re treatme 
and follow up - if not, defaulter and therefore not suitable for this 
category 
2 
22.1 Address (ADDRESSOl): 
street address of child 
lmoved = child moved outof study-area - didn't complete treatment 
moved = moved, but completed treatment (This is used for monthly follow-up recalls - to make it easier for 
the clinic sister to find the child) 
24. History - Duration of illness (HISTORYDUR): 
Numberic value counted in weeks 
25-32. Cough (COUGH), Fever (FEVER), Wheeze (WHEEZE), Loss of appetite (LOSSAPPETI), Loss of weight (LOSSWEIGHT), Sweats (SWEATS), List-
lessness (LISTLESSNE), Breathless (BREATHLESS) 
"y" = yes 
"n" = no 
33. Other (list) (OTHERLIST): 
If recent admission to a hospital; name of hospital, reason of stay duration of stay 
Comments by medical docter - if no comments; type in "none" 
34. Contact Specify who (CONTACTSPE): 
Only adult index cases are important 
Folder number next to name eg. Nel,Jan Xl 
34.1 Record number of CONTACT.REC (CONTACTSPl): 
Detailed information of specific child's contact in CONTACT.REC -
record number specified 
35. BCG Date given (BCGDATEGIV): 
American date order 
36. BCG Scar present (SCARPRESEN): 
"y" = yes 
"n" = no 
37-40. Social Number of adults (SOCIALNUMB), Number of children (NUMBERCHI Sleeping rooms per house (SLEEPINGRO), Number of adults employed (NUMBERADUL): 
Numeric values 
41,43-46, 
48,50,52, 
53,54. Lymphadenopathy (LYMPHADENO), Erythema nodosum (EN), 
Phlytenular conjunctivitis (PC) Abdominal glands (ABDGLANDS), 
Hepar (HEPAR), Spleen (CMSPLEEN), Respiretory Distress (RESPDISTRE), accessory muscle use (ACC), 
grunting (GRUNT), cyanosis (CYAN): 
"Y" = yes 
"n" = no 
3 
42. Site and size (SITESIZE): 
Short comments by medical docter re lymphadenopathy 
47,49,51. Size (SIZE), size (SIZEOl), Rate of breathing if has respiratory 
distress (RATE): 
Numeric values 
55. Other (OTHER): 
Remarks by medical docter re the physical condition of the child 
eg. Scabies, orange hair etc. 
56. Investigations TST (Tuberculin Skin Test) tine grade (TSTTINEGRA): 
Numeric values 1 - 4 
Initial tine test result 
57. Mantoux (ORMANTOUX): 
Numeric value in millimeters 
Initial skin test result 
58. Tine grade 12 mth (TINEGRADEl): 
Numeric value 1 - 4 
Tine test result - 12 mth's after treatment commenced 
59-67. CXR hilar adenopathy only (CXRHILARAD), segmental lesion only (SEGMENTALL), both of the above (BOTHABOVE), pleural effusion (PLEURALEFF), cavitatory disease (CAVITATORY), miliary (MILIARY), 
bronchogenic (BRONCHOGEN), merely suspicious (MERELYSUSP), 
NAD (NAD) 
y = yes 
n = no 
This part of the questionnaire is filled in after the panel of 
specialists evaluated the x-rays of the children. 
68. Sputum investigation (SPUTUMINVE): 
y = yes 
n = no 
69. microscopy+ (MICROSCOPY): 
y = yes 
n = no 
70. culture+ (CULTURE): 
y = yes 
n = no 
(68 -70 sputum investigations in children are very seldom done) 
71,72,74-79. Diagnostic category: Intrapulmonary -TB ... (INTRAPULMO), 
Extrapulmonary -TB ... (EXTRAPULMO), Case Definite (CASEDEFIN 
Probable (PROBABLE), Suspect (SUSPECT), Tuberculin reactor (TUBERCULIN), Contact (CONTACT): 
4 
y = yes 
n = no 
This part of the questionnaire is filled after the panel visi 
Cases (CASES): Numeric value (used by research-assistant) 
1 = Definite case 
2 = Probable case 
3 = Suspect case 
73. Specify (SPECIFY): 
Short comment by specialists. 
80. (a) Follow up date (FOLLOWUPDA): 
American date order 
Recall date for chest X-rays, clinical investigation by medical docter 
Usually at 3,6,12,30 months after treatment has started. (b) Followup date (FOLLOWUPD1): 
A numeric value of "12'' is typed in if it's time for the 12 month foll 
up. This is done to remind the clinic sister to repeat the tine test. 
This information is used by the research-assistant to recall children 
monthly. 
"99" is typed in if the respondent was already discharged, but 
still for follow-up. 
81-85. Date3 mth assess (DATE3MTHAS), Date6 mth assess (DATE6MTHAS), 
Datel2 mth assess (DATE12MTHA), Date30 mth assess (DATE30MTHA), 
The follow-up assessments are based on the quantity of doses the 
child received to date - the real time aspect is not always reliabl 
The "12" and 11 30 11 month follow-up though are respectively based 
on the time after treatment commenced - 11 12 month follow-up" 10-17 
months after treatment commenced and "30 month follow-up" 18-30 
months after treatment commenced. 
(DATE30MTH1) This numeric value represents the exact time the 30 
month follow-up was performed. 
85,86. Weight3 (WEIGHT3), Height3 (HEIGHT3): 
Numeric values 
Weight measurement and height if the child is >3 years old, length 
measurement if the child is <3 years old. The child has completed 
26 or 60 doses respectively. 
88,89. Weight6 (WEIGHT6), Height6 (HEIGHT6): 
Same as 74,75 
The child has completed 52 or 120 doses respectively. 
91,92. Weightl2 (WEIGHT12), Heightl2 (HEIGHT12): 
Same as 74,75 
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Measurements taken 10-17 months after treatment commenced. 
94,95. Weight30 (WEIGHT30), Height30 (HEIGHT30): 
Same as 74,75 
Measurements taken 18-30 months after treatment commenced. 
87,90,93,96. outcom3 score (OUTCOM3SCO), outcom6 score (OUTCOM6SCO), 
Outcom12 score (OUTCOM12SC), Outcome30 score (OUTCOM30SC): 
Numeric value -4 to +8 
Scoring is done by the medical doctor in co-operation 
with the specialists. 
See protocol by Dr te Water Naude 
Twice Weekly: 
3 month score= (20 - 40) doses 
6 month score= (33 - 77) doses 
Standard regime: 
3 month score= (46 - 94) doses 
6 month score= (95 - 135) doses (The following codes are used by the research-assistant: 
20 = wait for chest X-rays 
21 = wait for sisters-report 
22 = impossible to score 
23 = didn't come for follow-up 
24 = moved) 
25 = administrative error 
97,99,101,103. Outcome Compliance: Doses3 (DOSES3)AND(DOSES4), Doses6 (DOS 
AND(DOSES7), Doses9 (D0SES9)AND(DOSES10), Dosesl2 (DOSES12) 
AND(DOSES13): 
Numeric values 
This represents the actual amount of treatment the child 
received over 3 months over the presumed amount of treatmen 
over a calendar time of 3 months. 
98,100,102,104. Compliance3 (COMPLIANCE), Compliance6 (COMPLIANCEOl), 
Compliance9 (COMPLIAN02), Compliance12 (COMPLIAN03): 
Percentage of 86,88,90,90 respectively 
105. IIT Completed: Month (IITCOMPLET): 
Numeric value 
Presumed duration of treatment expressed in months. (The following code words are used by the research-assistant: 
3* = Treatment was incorrectly stopped; error was discovered 
2 months after it was stopped 
2TS = Two treatment sheets in file - child had received TB-Rx 
before. 
62+5 = received Intermittent therapy and Standard therapy during the 
period of treatment - reasons: administrative errors, 
admitted in hospital, study MO changed therapy (rec 116), 
took therapy twice weekly on standard therapy regimen, 
6 
took therapy 5 days/week on twice weekly regimen. 
6+6 = child received 6 months treatment, compliance was poor, 
specialists decided on another 6 months of Rx. 
6+R = child was seen by other MO; by mistake put on Rifater 
40 doses. 
SH = received Rx for 2 months in hospital+ 6 months of ST 
with us. 
9 = child never came for 3 and 6 month follow-up, after 9 
months saw MO and Rx was stopped. 
11 = Enrolled to take ST for 6 months, vomited and specialists 
decided on Rx for another 30 doses (TBH - enterocolitis). 
12 = Child was enrolled to take ST for 6 months, by mistake 
received IT (120 doses). 
wait= wait for completed treatment sheet from the clinic 
lost= treatment sheet is lost; impossible to complete question 
notb = specialist changes diagnoses; received TB treatment but not 
really TB-sufferer 
ros = regime other than study 
106, Doses (DOSES)AND(DOSESl): 
Numeric values 
The doses the child received from day one of treatment till the day 
treatment is stopped, over the presumed amount over the exact calenda 
period of treatment. 
107. Compliance (COMPLIAN04): 
Numeric value 
Percentage of 95. 
108. Defaulter (DEFAULTER)AND(DEFAULTERl): 
(a) y = yes 
n = no 
(b) 1 = bad compliance 
2 = defaulted for >2 months 
109. Excluded form study (EXCLUDEDFR): 
1 = moved to homelands (Transkei, Ciskei) 
2 = moved out of study-area 
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3 = defaulted 
4 = diagnosis (changes in opinions) 
5 = incomplete initial data 
6 = drug reaction while on or reaction to treatment 
7 = previous TB treatment 
8 = ineligible for enrollment 
9 = hospital admission 
10 = Treatment incorrect 
11 = other 
110. Relapsed (RELAPSED): 
If "Y" = child possibly relapses - for specialists' evaluation. 
111. N12score and N30score 
On the 11/9/94 it was decided to exclude the mother's assessment 
from the score criteria at 12 and 30 months. 
A new numeric variable was created with the denominator= 6. 
Previous scores were re-entered subtracting the points for the mother' 
assessment. 
8 
Appendix 6: Programme written to derive data from the database 
Please note: this is a number of programmes combined. 
Read C:\epi6\data6\stb.rec 
define case# 
If cases =1 or cases =2 or cases =3 then case =1 else case =O 
If cases =1 or cases =2 or cases =3 then cases =6 
If stellenbos =6 or stellenbos =8 then stellenbos =2 
If stellenbos =7 or stellenbos =9 then stellenbos =5 
Let deftime = ( DATEFIRSTD - VISITDATE) 
Define cramin ###.## 
let cramin = ( SOCIALNUMB + NUMBERCHIL/2) / SLEEPINGRO 
Define dose%### 
if stellenbos = 2 then dose%= 100 * ( N1ST4WEEKS + N2ND4WEEKS + N3RD4WEEKS 
if stellenbos = 5 then dose%= 100 * ( N1ST4WEEKS + N2ND4WEEKS + N3RD4WEEKS 
Define dosecat # 
if dose% >=75 then dosecat =1 
if dose%< 75 then dosecat =O 
Define cramcat # 
if cramin >2.5 then cramcat =1 
if cramin <=2.5 then cramcat =O 
Define discat # 
If SEGMENTALL = "Y" or BOTHABOVE = "Y" or CAVITATORY = "Y" or BRONCHOGEN = 
define contaxcat # 
if CONTACTSPE = "no adult contacts" then contaxcat =O else contaxcat =1 
define d%1 ### 
let d%1 = 100 * nlst4weeks/ nlst4weekl 
define d%2 ### 
let d%2 = 100 * n2nd4weeks/ n2nd4weekl 
define d%3 ### 
let d%3 = 100 * n3rd4weeks/ n3rd4weekl 
define d%4 ### 
let d%4 = 100 * n4th4weeks/ n4th4weekl 
define d%5 ### 
let d%5 = 100 * n5th4weeks/ n5th4weekl 
define d%6 ### 
let d%6 = 100 * n6th4weeks/ n6th4weekl 
define dl # 
if d%1 < 75 then dl = o 
if d%1 >=75 then dl = 1 
define d2 # 
if d%2 < 75 
if d%2 >=75 
define d3 # 
if d%3 < 75 
if d%3 >=75 
define d4 # 
then 
then 
then 
then 
d2 
d2 
d3 
d3 
= 0 
= 1 
= 0 
= 1 
1 
if d%4 < 75 then d4 = 0 
if d%4 >=75 then d4 = 1 
define d5 # 
if d%5 < 75 then d5 = 0 
if d%5 >=75 then d5 = 1 
define d6 # 
if d%6 < 75 then d6 = 0 
if d%6 >=75 then d6 = 1 
define d12 ### 
let dl2 = d%1 + d%2 
define dl-100 # 
if d%1 < 100 then dl-100 
if d%1 >=100 then dl-100 
define d12-175 # 
if d12 < 175 then d12-175 
if d12 >=175 then d12-175 
route C:\06a\resultz.6a3 
tables cases stellenbos 
select cases =6 
tables sex stellenbos 
means age 
means age stellenbos 
means weight 
means weight stellenbos 
means warn 
means warn stellenbos 
means height 
means height stellenbos 
means cramin 
means cramin stellenbos 
select ham <999 
means ham 
means ham stellenbos 
select cases =6 
select outcom3sco <20 
= 
= 
= 
= 
means outcom3sco stellenbos 
select 
select cases =6 
select outcom6sco <20 
means outcom6sco stellenbos 
tables dosecat STELLENBOS 
tables STELLENBOS dosecat 
select 
means Dl-100 dosecat 
means cramin dosecat 
means cramin any 
tables Dl-100 any 
define d23456 ### 
0 
1 
0 
1 
if STELLENBOS =2 then d23456 =100*( N2ND4WEEKS + N3RD4WEEKS + N4TH4WEEKS + if STELLENBOS =5 then d23456 =100*( N2ND4WEEKS + N3RD4WEEKS + N4TH4WEEKS + 
2 
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